**CURRICULUM VITAE**

**David C. Mulligan, MD, FACS**

**Version date:**  10/26/2022

**Proposed for Appointment:** Professor, Clinician-Educator, Department of Surgery

## Term: Primary Appointment

**School:** Yale University School of Medicine

**Education:**

1977–1981 BA, Bellarmine College, Chemistry and Biology

1982-1986 M.D. University of Louisville School of Medicine

2014 MPA, Yale University 2014

**Career/Academic Appointments:**

July 1986- June 1987 Internship, General Surgery, University of Louisville

July 1987- June 1988 Residency, General Surgery, University of Louisville

July 1988- June 1991 Residency, Urologic Surgery, University of Louisville

July 1991- June 1993 Residency, General Surgery, Case Western Reserve University

July 1993- June 1995 Fellowship, Multi-Organ Transplantation, Baylor University Medical Center, Dallas, TX

July 1995- Aug 1998 Assistant Professor of Surgery – Case Western Reserve University, Cleveland, Ohio

July 1995- Aug 1998 Director of Liver Transplantation – University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio

Oct 1998- Aug 2013 Chair, Hepatobiliary and Pancreatic Surgery – Division of Transplant Surgery, Department of Surgery, Mayo Clinic, Scottsdale, Arizona

July 1999- June 2002 Assistant Professor of Surgery – College of Medicine, Mayo Clinic

July 2002- June 2006 Associate Professor of Surgery – College of Medicine, Mayo Clinic

July 2006- Aug 2013 Professor Surgery, College of Medicine, Mayo Clinic

July 2010- Aug 2013 Director, Transplant Center, Mayo Clinic, Phoenix, AZ

Sept 2013 – present Division Chief, Transplant Section, Department of Surgery, New Haven, CT

**Administrative Positions:**

July 1998- August 2013 Consultant, Division of Transplant Surgery, Department of Surgery, Mayo Clinic, Scottsdale, AZ

July 1999- August 2013 Surgical Director, Division of Transplant Surgery, Department of Surgery, Mayo Clinic, Scottsdale, AZ

July 2006- August 2013 Professor Surgery, College of Medicine, Mayo Clinic

July 2012- August 2013 Director, Transplant Center, Mayo Clinic, Phoenix, AZ

Sept 2013 – present Division Chief, Transplant Section, Department of Surgery, New Haven, CT

June 2023 – present Board of Directors member,American Society of Transplant Surgeons, Arlington, VA

**Board Certification:**

1994- Present American Board of Surgery, Diplomate

1987- Present National Board of Medical Examiners (NBME), Diplomate

**Professional Honors & Recognition:**

***International/National/Regional***

2015-21 Castle Connolly Top Doctors, Connecticut

2006: Distinguished CME Educator – Mayo Clinic in Arizona

2006: Distinguished Mayo Clinician – Mayo Clinic in Arizona

2001 Castle Connolly, Top Doctors, Arizona

1997: Presley F. Martin, M.D. Memorial Award

1997: Student Affairs Award for Outstanding Leadership

1997: Special Recognition Award for Outstanding Senior Student – Alpha Omega Alpha Honor Medical Society

1994: Five Star Spirit Award – Baylor University Medical Center

1986: Senior Honors Student in Surgery – University of Louisville School of Medicine

1984: Outstanding Young Men in America – Jaycees

1983-86 Class President – University of Louisville School Medicine

1982-83 Class Vice-President – University of Louisville School of Medicine

***University***

2021-22 Charles W. Bohmfalk Prize for Teaching in Clinical Sciences, Yale School of Medicine, New Haven, CT

2015 Masters Privatum – Yale University, New haven, CT

**Grants/Clinical Trials History:**

***Past Clinical Trials***

A Randomized, Prospective, Double-Blinded Evaluation

of Selective Bowel Decontamination in Liver Transplantation. (1469-98).

Co- Principal Investigator

1998-2002

Ischemia-Reperfusion Injury Funded by J. Orin Edson Foundation.

Co- Principal Investigator

 Clinical Utility of the Mayo End-Stage Liver Disease Model

Score for Following Patients Awaiting Orthotopic Liver Transplantation. (2166-00)

Co- Principal Investigator

2002-2004

A Pilot Study Using Intron A (Interferon alfa-2b) or

Pegylated Intron A Plus Ribavirin for Treatment of Recurrent

Hepatitis C Virus Following Transplantation. (499-00).

Co- Investigator

200-2003

Prevalence of Osteoporosis in Patients with End-Stage

Liver Disease. (2229-00)

Co-Principal Investigator

2000-2004

The Effect of HCV on Outcomes of Resection for 200

Hepatocellular Carcinoma (HCC) in th MayExperience.(2053-00).

Co Principal Investigator

2002-2004

           Renal Cell Carcinoma Metastatic to Pancreas. (2075-00)

Principal Investigator

2002-2004

Biliary Complications Associated with CMV Hepatitis in

Orthotopic Liver Transplant. (2203-00)

Principal Investigator

2000-2002

Tacrolimus Use in a Liver Flush Solution to Decrease

Reperfusion Injury Following Liver Transplantation. (101-00).

Principal Investigator

2000-2002

"Does Diabetes Mellitus Influence Hepatitis C Virus (HCV)”. (1239-01).

Principal Investigator

2001-2002

Screening Colonoscopy Prior to Liver Transplantation (1533-01).

Co- Investigator

2001-2002

"A Prospective, Randomized Trial of Calcineurin-Inhibitor

Withdrawal in Renal Allograft Recipients". (124-01).

Co- Investigator

2001-2011

"A Multi-Center Study of the Safety and Efficacy of

N-Acetylcysteine in the Treatment of Acute Liver Failure

Not Caused by Acetaminophen". (1088-01)

Co- Investigator

2001-2008

"Cancer Tissue Study". (2130-00)

Other Staff Study

2/2001-7/2004

An Open Randomized, Prospective Multicenter Study to

Compare the Efficacy and Safety Among Three

Immunosuppressant Treatment Regimens in Patients

Receiving a Liver Transplant for End-Stage Liver Disease

Caused by Chronic Hepatitis C (1202-02).

Co – Investigator

2002-2007

A Randomized, Open-Label, Comparative Evaluation of

Conversion from Calcineurin Inhibitor Treatment to Sirolimus

Treatment Versus Continued Calcineurin Inhibitor Treatment

in Liver Allograft Recipients Undergoing Maintenance Therapy. (1780-02).

Co- Investigator

2002-2003

Chart Review for Factors Affecting Kidney Transplan Patients

with Documented CMV Disease. (2101-03).

Co – Investigator

2003-2004

A Pilot Phase II Multicenter, Randomized Double-Bilateral

Placebo Controlled, Dose Escalation Study of the Safety

and Efficacy of a Human HCV-Antibody (HCV-Ab XTL 68)

for Prevention of Hepatitis C Disease Recurrence in Patients (2-03).

Co- Investigator

2003-2006

Chart Review for Factors Affecting Kidney Transplant Patients

with Documented CMV Disease. (2101-03)

Co- Investigator

"A One-Year, Multicenter, Partially Blinded, Double-Dummy,

Randomized Study to Evaluate the Efficacy and Safety of

FTY720 Combined with Reduced Dose or Full-Dose

Neoral and Corticosteroids Versus Mycophenolate

Mofetil (MMF, CellCept) C " (1311-03).

Co- Investigator

2003-2007

CL-000006556-PRO-0006: Caspase Inhibitor, IDN-6556,

in OLT. Funded by IDUN Pharmaceutical.

Principal Investigator

2003-2004

"Assessment of Hepatobiliary Anatomy After Donor

Hepatectomy for Living Donor Liver Transplantation"

MCS087. (130-03).

Principal Investigator

2003-2007

Use of Prostaglandin E1 in High Risk Liver Transplant

Recipients Improves Early Graft Function. (2268-03).

Principal Investigator

2003-2004

Retrospective Review of Alprostdil Use in the Early

Post-Liver Transplant Setting, Beneficial or Not? (2102-03)

Principal Investigator

2003-2004

Safety, Tolerability and Efficacy Study of a Caspase

Inhibitor, IDN-6556, in Patients Undergoing Orthotopic

Liver Transplantation (OLT). (1369-03).

Co-Principal Investigator

"A Prospective, Randomized, Multicenter, Open-Label,

Comparative Safety and Efficacy Study of Prophylactically

Administered Pegylated Interferon alfa-2a (Pegasys®)

Plus Ribavirin vs. No Prophylaxis Following

Liver Transplantation for He...". (1404-04).

Co -Investigator

2004-2009

"Quality of Life Among Living and Deceased

Donor Liver Transplant Recipients". (2461-04).

Other Staff Study

2004-2009

"Kidney Transplantation in Patients with Positive Flow Crossmatch". (2368-04).

Co-Investigator

2004-2007

SV40 Pathogenesis of Human Infections. Funded by

National Institute of Allergy and Infectious Diseases.

(R01 CA104818).

Co- Investigator

2004-2009

"Randomized Trial of Thymoglobulin Induction, Initial

Tacrolimus and Mycophenolate Mofetil Therapy with

Steroid Avoidance in Primary Kidney Transplant Recipients

Followed by Continued Tacrolimus/Mycophenolate

Mofetil Therapy" (37-05).

Co- Investigator

2005-2011

The Effect of Donor Hepatectomy on the Pharmacokinetics

of Fentanyl, Vecuronium and Dexmedetomidine. (923-05).

Co- Investigator

"Non-Invasive Evaluation of Pulmonary Vascular Resistance

in Patients with End Stage Liver Disease". (1012-05).

Co – Investigator

2005-2007

"A Prospective, Open-Label, Multi-Center, Randomized Trial of the Efficacy and Safety of a Long Term Calcineuri Inhibitor Free Maintenance Regimen with Mycophenolate Mofetil and Sirolimus in Recipients of an Orthotopi Transplant". (1462-05).

Co- Investigator

"A Phase IV, Randomized, Open-Label, Comparative,

Multicenter Study to Assess the Safety and Efficacy of

Induction Agents Alemtuzumab (Campath 1H), Basiliximab

(Simulect) or Rabbit Anti-Thymocyte Globulin (Thymoglobulin).

In Combination...". (1740-05).

Co- Investigator

2005-2009

A 24-Month, Multicenter, Randomized, Open-Label

Co- Investigator

2006 – 2007

Non-Inferiority Study of Efficacy and Safety Comparing

Concentration-Controlled Certican in Two Doses

(1.5 and 3.0 mg/day starting doses) With Reduced

Neoral vs. 1.44 g Myfortic With Standard Dose Neoral

in de novo Renal Transplant Recipients. Novartis.

Co- Investigator

A Phase IIIb, Randomized, Open-Label, Comparative,

Multi-Center Study to Assess the Safety and Efficacy of

Prograf vs. Modified Release Tacrolimus (MR) With

CellCept and Steroid Withdrawal in de novo Liver

Transplant Recipients. Astellas Pharma US, Inc. (06-003069)

Co- Investigator

2006-2

Steroid avoidance in kidney transplant recipients with obesity. (06-005278).

Co- Investigator

2006-2009

07-003467/ViroPharma 1263-301/ Maribavir Versus

Oral Ganciclovir in: Maribavir Versus Oral Ganciclovir for

the Prevention of Cytomegalovirus Disease in Recipients

of Orthotopic Liver Transplants. Funded by ViroPharma Incorporated.

Co- Investigator

2007-2009

The role of neo adjuvant and adjuvant chemo and radiation

therapy in patients undergoing surgical resection for pancreatic

adenocarcinoma, neuroendocrine malignancy, cholangiocarcinoma,

hepatic malignancy and other hepato-pancreato-biliary cancers. (07-000990).

Co- Investigator

2007-2008

Donor and Recipient Outcomes of Living Donor

Liver Transplantation. (07-003831).

Principal Investigator

2007-2010

Does Plavix increase the risk of complications after kidney transplantation? (07-004833).

Co- Investigator

2007-2010

A Randomized, Double-Blind Study to Assess the Efficacy

and Safety of Prophylactic Use of Maribavir Versus Oral

Ganciclovir for the Prevention of Cytomegalovirus Disease

in Recipients of Orthotropic Liver Transplants.

ViroPharma Incorporated. (07-003467).

Co- Investigator

2007-2010

Comparison of Glucose Metabolism Post Transplantation

Among Diabetic Patients Receiving Simultaneous Pancreas

and Kidney Transplant and Non- Diabetic Patients Receiving

Kidney Transplantation. (07-003287).

Co- Investigator

2007-2011

Pancreas transplantation using rapid steroid taper and

protocol biopsies. (07-008137).

Co – Investigator

2007-2011

Influence of Genetic Polymorphisms on Tacrolimus

Metabolism Among Native Americans.

Astellas Pharma US, Inc. (07-004306).

Co- Investigator

2007-2012

IM103-045 Evaluation of Belatacept as First-line

Immunosuppression in De Novo Liver Transplant Recipients.

Bristol-Myers Squibb. (07-006244).

Co- Investigator

2008-2012

Economic impact of recipient MELD score, donor risk

index, MELD exceptions on hospital utilization. (08-000476).

Co – Investigator

2008-2009

The role of neo adjuvant and adjuvant chemo and radiation

therapy in patients undergoing surgical resection for pancreatic

adenocarcinoma, neuroendocrine malignancy, cholangiocarcinoma,

hepatic malignancy and other hepato-pancreato-biliary cancers. (08-003320).

Co- Investigator

200

Intraductal Papillary Mucinous Neoplasm in Liver Transplant Recipients. (08-006232).

Co- Investigator

2008-2009

Review of Glucose Metabolism and Post Transplantation

Outcomes Among Type 2 Diabetic Patients Receiving

Simultaneous Pancreas and Kidney Transplant. (08-000156).

Co- Investigator

2008-2010

Genetic Alterations of Hepatocellular Carcinoma Associated

with Shorter Recurrence-Free and Overall Survival Following

Orthotopic Liver Transplantation (08-001026).

Co- Investigator

2008-2010

The Coronary Screening for Kidney Transplantation (COST)

Study: Feasibility Phase Study. National Institutes of Health

(NIH): subcontract w U of Minnesota. (08-001949).

Co – Investigator

2008-2010

New Onset Diabetes Mellitus after Liver Transplantation (08-001324).

Co- Investigator

2008-2011

ediate Post-Transplant Period After Solid Organ Transplantation. (08-005602).

Co- Investigator

2008-2013

WOUND COMPLICATIONS AFTER KIDNEY TRANSPLANTATION.

no funding necessary. (09-004819)

Co- Investigator

2009-2010

A Phase 2, Open-Label, Multi-Center, Randomized Trial To

Demonstrate the Pharmacokinetics Of LCP-Tacro™

Tablets Once Daily and Prograf® Capsules Twice Daily In

Adult De Novo Liver Transplant Patients (LCP-Tacro 2018).

LifeCycle Pharma. (08-007672).

Co – Investigator

2009-

LifeCycle 2018/A PHASE 2, OPEN-LABEL, MULTI-CENTER,

RANDOMIZED TRIAL TO. Funded by Life Cycle. (2018).

Co- Investigator

2009-2010

Outcomes of Renal Transplant Recipients Utilizing Expanded

Criteria Donors. No specific Mayo funds required.

Chart review only. (09-004620).

Co- Investigator

2009-2013

12414, A Phase III randomized, double-blind,

placebo-controlled study of sorafenib as adjuvant

treatment for hepatocellular carcinoma after surgical

resection or local ablation. Bayer HealthCare Pharmaceuticals:

CRO is Covance. (08-004479).

Co- Investigator

2009-2013

Vargas/07-006244/Evaluation of Belatacept as First-line

Immunosuppression in De Novo Liver Transplant Recipients

in: Extension: Evaluation of Belatacept as First-line

Immunosuppression in De Novo Liver Transplant Recipients.

Funded by Bristol-Myers Squibb Pharmaceutical.

Co- Investigator

2009-2011

A Collection Protocol for Patients with Pancreatic Cancer

to Provide Blood Components Via Leukapheresis For

Investigations in Pancreatic Cancer Immunotherapy.

National Institute of Health. (09-003635).

Other Staff Study

11/2009 – 10/2013

Prospective Analysis of Predictors of New Onset Diabetes

After Liver Transplantation. Mayo CR5. (09-007440).

Co- Investigator

01/2010 – 12/2013

A Prospective, Multicenter Comparison of Multiphase

Contrast Enhanced CT and Multiphase Contrast Enhanced

MRI for Diagnosis of Hepatocellular Carcinoma and Liver

Transplant Allocation. ACRIN-American College of Radiology

Imaging Network. (10-005978)

Other Staff Study

02/2011 – 01/2014

Utilization of Organs for Transplantation from Center for

Disease Control High Risk Donors: A Single Center review.

No specific Mayo funds. (11-004892).

Co- Investigator

2011 – 2013

Frailty and sarcopenia in candidates for liver transplantation.

No funding. (11-0

Co-Investigator

2011-2013

A Phase 2/3, Double-Blind, Placebo-Controlled,

Two-Part Study (Part 1 Open-Label) to Assess the Safety,

Efficacy and Pharmacokinetics of Single Intravenous

Doses of ASP8597. (Diannexin) in de novo Kidney Transplant Recipients.

Astellas Pharma Global Development, Inc. (11-007615)

Co- Investigator

2012-2013

Feasibility Study: Using Resolution, MD for remote image

viewing. Radiology Department at Mayo Clinic in AZ.

(12-000582)

Co- Investigator

02/2012 – 02/2014

Biopsy Outcomes of Kidneys from Deceased Donors with

Acute Kidney Injury. no funding needed. (11-006465)

Co- Investigator

03/2012- 02/2014

A Pilot Study to Characterize Flow-Sorted Genomics in

Patients with Advanced Biliary Tract Cancers. CR5 Award

Mayo Clinic Arizona. (12-002196).

Co- Investigator

05/2012 – 04/2014

A Prospective, Single-blind, Randomized, Phase III Study

to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols

(FS Grifols) as an Adjunct to Hemostasis During Parenchymous

Tissue Open Surgeries.  Sponsor:  Grifols, PI:  Sukru Emre.  $43,958

Co- Investigator

2013-2016

Eculizumab for Prevention of Delayed Graft Function in

Deceased Donor Kidney Transplantation Aim: A pilot prospective,

randomized study to test the efficacy of eculizumab

(vs. placebo; given once at the time of transplantation and

once 24 hours later) in preventing.  DGF in first adult

recipients of deceased donor kidneys.

Sponsor:  Icahn School of Medicine at Mount Sinai.

PI:  Sanjay Kulkarni.

Co- Investigator

2014-2016

Analysis of the Risk of Daytime vs Nighttime Interventional

Radiology Biopsies at Yale-New Haven Hospital

Agency: Yale University School of Medicine

HIC#: 1412015038. Percent Effort: N/A

Principal Investigator

2014-2016

Evaluation of Acute Rejection in de novo Renal Transplant

Recipients Following Thymoglobulin Induction, CNI-Free,

Nulojix (belatacept) – based Immunosuppression (IM 103-177).

Aim: The primary objective is to assess the incidence of clinically-

suspected and biopsy proven acute rejection (CSBPAR) at 6 months

post-transplant in de novo renal allograft recipients treated with

thymoglobulin induction, rapid corticosteroid withdrawal, and

maintenance belatacept in combination with MMF or EVL, or

maintenance TAC in combination with MMF.

Sponsor:  Bristol Myers-Squibb.  PI:  Richard Formica.  $250,699

Co Investigator

2015-2016

A Randomized, Parallel-Group, Double-Blind, Placebo-

Controlled Multi-Center Study of Eculizumab for the Prevention

of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function (PROTECT Study) Alexion Pharmaceuticals, Inc.,

P.I. Sanjay Kulkarni.

Percent Effort: N/A

Sub- Investigator

2015-2016

QPI-1002 for Prevention of Delayed Graft Function in

Recipients Of an Older Donor Kidney Transplant (ReGIFT)

Agency: Quark Pharmaceuticals Inc.

I.D.# HIC#1510016593. P.I. Sanjay Kulkarni

Percent effort: N/A

Sub- Investigator

2015-2019

Impact of Perioperative Frailty on Perioperative Outcomes

In Patients Undergoing Renal Allotransplantation

PI: Ranjit Deshpande

Total costs for project: N/A

Sub- Investigator

2017-2020

### Effects of Inhibiting Early Inflammation in Kidney Transplant

### Patients: Randomized Controlled Trial of Infliximab (Remicade®)

### Induction Therapy For Deceased Donor Kidney Transplant

### Recipients (U01 AI063594-11).  Aim: The objective of the study is to

### determine the efficacy of intravenous infliximab administered at the time of transplantation, prior to reperfusion, on 2-year kidney transplant survival and function.

###  PI:  Peter Heeger,

Site PI:  Richard Formica.  $190,850 annually

Co – Investigator

2015-2021

David Mulligan, MD

Title: Living Donor Liver Transplantation: Yale Experience

HIC: 20000021010

Unfunded

Principal Investigator

HERCULES:  Hepatitis C Positive Organ to Recipient Hepatitis

C Negative Longitudinal Transplant Study Compare time to

Transplant for Registrants Listed to Consider Allografts from

 HCV NAT+ Donors Versus those who are not.

Unfunded

Co- Investigator

5/24/2019

***Federal***

Adult to Adult Living Donor Transplantation

Funded by NIH in Collaboration with Mayo Clinic Rochester

Application funded for Federal Grant

Co- Investigator

2009-2014

SV40 Pathogenesis of Human Infections.

Funded by National Institute of Allergy and

Infectious Diseases.

(R01 CA104818)

Co- Investigator

2004-2009

***Foundation***

The Investigation of NF-kB Inhibition in Prevention

of Ischemia-Reperfusion Injury.

Funded by J. Orin Edson Foundation.

Principal Investigator

2000-2002

***Industry***

Maribavir Versus Oral Ganciclovir in: Maribavir

Versus Oral Ganciclovir for the Prevention of

Cytomegalovirus Disease in Recipients of Orthotopic

Liver Transplants.

07-003467/ViroPharma 1263-301

Funded by ViroPharma Incorporated.

Co- Investigator

2007-2009

A PHASE 2, OPEN-LABEL, MULTI-CENTER, RANDOMIZED

1/2009-12/2010

TRIAL TO.

LifeCycle 2018/

Funded by Life Cycle. (2018)

Co- Investigator

Caspase Inhibitor, IDN-6556, in OLT

Funded by IDUN Pharmaceutical.

CL-000006556-PRO-0006:

Principal Investigator

11/2003-10/2004

Funded

Evaluation of Belatacept as First-line

Immunosuppression in De Novo Liver Transplant

Recipients in: Extension: Evaluation of Belatacept as

First-line Immunosuppression in De Novo Liver

Transplant Recipients.

Funded by Bristol-Myers Squibb Pharmaceutical.

Vargas/07-006244/

Co- Investigator

2003-2004

***Mayo Clinic***

Assessment of biliary tree by MRCP

Funded by Mayo Protocol

Principal

2003-2004

***Mayo IRB Protocol***

Prospective Analysis of Predictors of New Onset

 Diabetes After Liver Transplantation. Mayo

CR5. (09-007440)

Co- Investigator

2010-2013

A Phase III randomized, double-blind, placebo-

controlled study of sorafenib as adjuvant treatment for

hepatocellular carcinoma after surgical resection or local ablation.

Bayer HealthCare Pharmaceuticals: CRO is Covance. 12414, (08-004479)

Co- Investigator

2009-2013

Utilization of Organs for Transplantation from

Center for Disease Control High Risk Donors:

A Single Center review. No specific Mayo funds. (11-004892)

Co- Investigator

2011-2013

Frailty and sarcopenia in candidates for liver

transplantation.

No funding. (11-007281)

Co- Investigator

2011-2013

A Collection Protocol for Patients with Pancreatic

Cancer to Provide Blood Components Via Leukapheresis

For Investigations in Pancreatic Cancer Immunotherapy.

National Institute of Health (09-003635) Other Staff Study

2009-2013

A Prospective, Multicenter Comparison of Multiphas Contrast Enhanced CT and Multiphase Contrast Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and

Liver Transplant Allocation

ACRIN-American College of Radiology Imaging Network.

(10-005978)Other Staff Study

2011-2013

Feasibility Study: Using Resolution MD for remote

image viewing.

Radiology Department at Mayo Clinic in AZ.

(12-000582)

Co- Investigator

2012-2013

Biopsy Outcomes of Kidneys from Deceased Donors

with Acute Kidney Injury. no funding needed.

(11-006465)

Co- Investigator

2012-2013

A Pilot Study to Characterize Flow-Sorted

Genomics in Patients with Advanced Biliary Tract Cancers.

CR5 Award Mayo Clinic Arizona.(12-002196) Co- Investigator

2012-2013

Other Study Staff:

"Cancer Tissue Study". (21300)2010-2013

***Completed***

Tacrolimus Use in a Liver Flush Solution to

Decrease Reperfusion Injury Following Liver

Transplantation. (101-00)

Principal Investigator

Renal Cell Carcinoma Metastatic to Pancreas.

(2075-00)

Principal Investigator

2000-2002

Biliary Complications Associated with CMV Hepatitis in

Orthotopic Liver Transplant. (2203-00)

Principal Investigator

2000-2002

"Does Diabetes Mellitus Influence Hepatitis C Virus

HCV” (1239-01)

Principal Investigator

2001-2002

"Assessment of Hepatobiliary Anatomy After

Donor Hepatectomy for Living Donor

Liver Transplantation" MCS087. (130-03)

Principal Investigator

11/2003/11/2004

Use of Prostaglandin E1 in High Risk Liver

Transplant Recipients Improves Early Graft

 Function. (2268-03)

Principal Investigator

07/2007-07/2010

Donor and Recipient Outcomes of Living Donor

Liver Transplantation. (07-003831)

Principal Investigator

07/2003 - 06/2006

Safety, Tolerability and Efficacy Study of a

Caspase Inhibitor IDN-6556, in Patients

Undergoing Orthotopic Liver

Transplantation (OLT). (1369-03)

Co- Principal Investigator

A Randomized, Prospective, Double-Blinded

Evaluation of Selective

Bowel Decontamination in Liver Transplantation. (1469-98) Co- Investigator

11/1998 - 07/2002

Prevalence of Osteoporosis in Patients with End- 12/2000 - 02/2004

Stage Liver Disease. (2229-00)

Co- Investigator

Clinical Utility of the Mayo End-Stage Liver

 Disease Model Score for Following Patients

Awaiting Orthotopic Liver Transplantation. (2166-00)

Co- Investigator

12/2000 - 11/2004

A Pilot Study Using Intron A (Interferon alfa-2b)

or Pegylated Intron A Plus Ribavirin for Treatment

of Recurrent Hepatitis C Virus

Following Transplantation. (499-00)Co- Investigator

12/2000 - 02/2003

"A Prospective, Randomized Trial of Calcineurin-

Inhibitor Withdrawal in Renal Allograft Recipients".

(124-01)

Co- Investigator

02/2001 - 11/2011

"A Multi-Center Study of the Safety and

Efficacy of N-Acetylcysteine in the Treatment

of Acute Liver Failure Not Caused By Acetaminophen". (1088-01)

Co- Investigator

06/2001 - 03/2008

Screening Colonoscopy Prior to Liver Transplantation. (1533-01)

Co- Investigator

10/2001 - 10/2002

An Open Randomized, Prospective Multicenter

Study to Compare the Efficacy and Safety Among

Three Immunosuppressant Treatment Regimens in

 Patients Receiving a Liver Transplant for End-Stage

 Liver Disease Caused by Chronic Hepatitis C... (1202-02)

Co- Investigator

07/2002 - 04/2007

A Randomized, Open-Label, Comparative Evaluation

 of Conversion from Calcineurin Inhibitor Treatment

 to Sirolimus Treatment Versus Continued Calcineurin

 Inhibitor Treatment in Liver Allograft Recipients

Undergoing Maintenance Therapy. (1780-02)

Co- Investigator

09/2002 - 09/2003

A Pilot Phase II Multicenter, Randomized Double-

Blind, Placebo Controlled, Dose Escalation Study of the

Safety and Efficacy of a Human HCV-Antibody

(HCV-Ab XTL 68) for Prevention of

Hepatitis C Disease Recurrence in Patients.... (2-03)

Co- Investigator

01/2003 - 10/2005

"A One-Year, Multicenter, Partially Blinded,

Double-Dummy, Randomized Study to Evaluate the

Efficacy and Safety of FTY720 Combined with Reduced

 Dose or Full-Dose Neoral and Corticosteroids

Versus Mycophenolate Mofetil (MMF, CellCept) C...". (1311-03) Co- Investigator

09/2003 - 11/2007

Chart Review for Factors Affecting Kidney

Transplant Patients with Documented CMV Disease. (2101-03)

Co- Investigator

10/2003 - 10/2004

Retrospective Review of Alprostdil Use in the

Early Post-Liver Transplant Setting, Beneficial or Not? (2102-03) Co- Investigator

10/2003 - 10/2004

"A Prospective, Randomized, Multicenter,

Open-Label, ComparativeSafety and Efficacy

Study of Prophylactically Administered Pegylated

Interferon alfa-2a (Pegasys®) Plus Ribavirin vs. No Prophylaxis

Following Liver Transplantation for He...". (1404-04)Co- Investigator

07/2004 - 05/2009

"Kidney Transplantation in Patients with

Positive Flow Crossmatch". (2368-04)Co- Investigator

11/2004 - 10/2007

"Randomized Trial of Thymoglobulin Induction,

Initial Tacrolimus and Mycophenolate Mofetil

Therapy with Steroid Avoidance in Primary

Kidney Transplant Recipients Followed by

Continued Tacrolimus/Mycophenolate Mofetil Therapy ...". (37-05)Co- Investigator

01/2005 - 10/2011

The Effect of Donor Hepatectomy on the

Pharmacokinetics of Fentanyl, Vecuronium and

Dexmedetomidine. (923-05) Co- Investigator

"Non-Invasive Evaluation of Pulmonary

Vascular Resistance in Patients with End

Stage Liver Disease". (1012-05)

Co- Investigator

05/2005 - 03/2007

"A Prospective, Open-Label, Multi-Center,

Randomized Trial of the Efficacy and Safety

of a Long Term Calcineurin Inhibitor Free

Maintenance Regimen with Mycophenolate

Mofetil and Sirolimus in Recipients of an

Orthotopic Liver Transplant". (1462-05) Co- Investigator

08/2005 - 04/2009

"A Phase IV, Randomized, Open-Label,

Comparative, Multicenter Study to Assess

the Safety and Efficacy of Induction Agents

Alemtuzumab (Campath 1H), Basiliximab

(Simulect) or Rabbit Anti-Thymocyte Globulin

(Thymoglobulin) In Combination...".

(1740-05)Co- Investigator

10/2005 - 08/2009

Steroid avoidance in kidney transplant

recipients with obesity.

(06-005278)Co- Investigator

09/2006 - 07/2009

A 24-Month, Multicenter, Randomized, Open-

Label Non-Inferiority Study of Efficacy and Safety

Comparing Concentration-Controlled

Certican in Two Doses (1.5 and 3.0 mg/day

starting doses) With Reduced Neoral vs.

1.44 g Myfortic With Standard Dose Neoral in de novo

Renal Transplant Recipients. Novartis. (06-003166)

Co- Investigator

09/2006 - 10/2007

A Phase IIIb, Randomized, Open-Label,

Comparative, Multi-Center Study to Assess the Safety and Efficacy

of Prograf vs. Modified Release Tacrolimus (MR)

With CellCept and Steroid Withdrawal in de novo

Liver Transplant Recipients. Astellas Pharma US, Inc. (06-003069)

Co- Investigator

11/2006 - 10/2007

The role of neo adjuvant and adjuvant chemo and radiation therapy in patients undergoing surgical

resection for pancreatic adenocarcinoma,

neuroendocrine malignancy, cholangiocarcinoma,

hepatic malignancy and other hepato-pancreato-biliary

cancers. (07-000990)

Co- Investigator

05/2007 - 05/2008

Transplantation Among Diabetic Patients

 Receiving Simultaneous Pancreas And Kidney

Transplant And Non- Diabetic Patients Receiving

Kidney Trasnplantation. (07-003287)

Co- Investigator

Does Plavix increase the risk of complications after kidney transplantation?

(07-004833)

Co- Investigator

07-2207-06/2010

A Randomized, Double-Blind Study to Assess

the Efficacy and Safetyof Prophylactic Use of

Maribavir Versus Oral Ganciclovir for the Prevention

of Cytomegalovirus Disease in Recipients of Orthotopic

Liver Transplants.

ViroPharma Incorporated. (07-003467)Co- Investigator

09/2007 - 02/2010

Influence of Genetic Polymorphisms on Tacrolimus

Metabolism Among Native Americans.

Astellas Pharma US, Inc. (07-004306)

Co- Investigator

11/2007 - 08/2012

Pancreas transplantation using rapid steroid taper and protocol biopsies.

(07-008137) Co-Investigator

11/2007-10/2011

Evaluation of Belatacept as First-line

Immunosuppression in De Novo Liver

Transplant Recipients. Bristol-Myers Squibb. (07-006244)

Co- Investigator

02/2008 - 01/2010

Economic impact of recipient MELD score,

donor risk index, MELD exceptions on hospital

utilization. (08-000476) Co- Investigator

02/2008 - 01/2009

New Onset Diabetes Mellitus after Liver

 Transplantation. (08-001324)Co- Investigator

2008 - 12/2011

Review of Glucose Metabolism and Post

Transplantation Outcomes Among Type 2 Diabetic

Patients Receiving Simultaneous

Pancreas and Kidney Transplant. (08-000156)

Co- Investigator

03/2008 - 12/2010

Genetic Alterations of Hepatocellular Carcinoma

 Associated with Shorter Recurrence-Free and

Overall survival Following Orthotopic Liver

Transplantation. (08-001026)

Co- Investigator

05/2008 - 04/2010

The role of neo adjuvant and adjuvant chemo

 and radiation therapy in patients undergoing

surgical resection for pancreatic adenocarcinoma,

neuroendocrine malignancy, cholangiocarcinoma,

hepatic malignancy and other hepato-pancreato-

biliary cancers. (08-003320) Co- Investigator

06/2008 - 05/2009

The Coronary Screening for Kidney

Transplantation (COST) Study: Feasibility Phase Study.

National Institutes of Health (NIH):

subcontract w U of Minnesota. (08-001949)

Co- Investigator

07/2008 - 05/2010

Hyperglycemia During the Immediate Post-

transplant Period After Solid Organ Transplantation.

(08-005602)

Co- Investigator

09/2008 - 06/2013

Intraductal Papillary Mucinous Neoplasm in Liver

Transplant Recipients. (08-006232)

Co- Investigator

09/2008 - 09/2009

A Phase 2, Open-Label, Multi-Center, Randomized

Trial To Demonstrate The Pharmacokinetics Of

LCP-Tacro™ Tablets Once Daily And Prograf®

Capsules Twice Daily In Adult De Novo Liver

Transplant Patients

(LCP-Tacro 2018).

LifeCycle Pharma. (08-007672)

Co- Investigator

01/2009 - 11/2010

Outcomes of Renal Transplant Recipients

Utilizing Expanded Criteria Donors. No

specific Mayo funds required.

Chart review only. (09-004620)

Co- Investigator

07/2009 - 05/2013

Wound Complications after Kidney Transplantation

No funding renecessary. (09-004819)

Co- Investigator

A Phase 2/3, Double-Blind, Placebo-Controlled,

Two-Part Study Part 1 Open-Label) to Assess the

Safety, Efficacy and Pharmacokinetics of Single

Intravenous Doses of ASP8597(Diannexin) in

de novo Kidney Transplant Recipients.

Astellas Pharma Global Development, Inc. (11-007615)

Co- Investigator

09/2012 - 01/2013

"Quality of Life Among Living and Deceased

Donor Liver Transplant Recipients". (2461-04)

Other Staff Study

11/2004 - 09/2009

A Phase III Randomized, Double-Blind Trial of

Chemoembolization with or without Sorafenib

in Unresectable Hepatocellular Carcinoma (HCC)

in Patients with or without Vascular Invasion.

NCI through cooperative groups grants. (10-004516)

Other Staff Study

**Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale: *International/National***

***International***

1. “An Unusual Cause of Failure of ESWL”

Society of University of Urologists Meeting

Toronto, Ontario, Canada ,1991

2. The Use of Anti-HCV Seropositive Organs in Liver Transplantation

David Mulligan, MD; Robert Goldstein, MD; Jeffrey Crippin, MD; Marwan Abouljoud, MD; Marlon Levy, MD; Bo Husberg, MD, PhD; Thomas Gonwa, MD; Goran Klintmalm, MD, PhD

XVth World Congress of the Transplantation Society

Kyoto, Japan,1994

3. Early Nutritional Support Via Enteral Route in Patients Undergoing Orthotopic Infection in Liver Transplantation (OLTX)

Cheryl Forde, RPh; Marlon Levy, MD; Linda Jennings, PhD; David Mulligan, MD; Marwan Abouljoud, MD; Robert Goldstein, MD; Bo Husberg, MD, PhD; Thomas Gonwa, MD; Goran Klintmalm, MD, PhD

XVth World Congress of the Transplantation Society,

Kyoto, Japan ,1994

4. Adenovirus Infection of the Human Intestinal Allograft

M Levy, MD; J Crippin, MD; D Mulligan, MD; S Holmberg, MD; R Goldstein, MD; B Husberg, MD, PhD; T Gonwa, MD; G Klintmalm, MD, PhD

the 4th International Symposium on Small Bowel Transplantation

5. Outcome of Anti-Hepatitis C Virus Seropositive Organs in Patients Following Liver Transplantation

David Mulligan, MD; Robert Goldstein, MD; Goran Klintmalm, MD; et al

7th Congress of the European Society for Organ Transplantation

Hoberg, Austria, 1995

6. Reduction of Early Rejection in Adult Liver Transplantation With ATG Induction Therapy

XVIth International Congress of the Transplantation Society

Barcelona, Spain, 1996

7. Intrathymic Spleen Cell Inoculation and ALS Fails to Induce Tolerance to Rat Pancreas Allografats

XVIth International Congress of the Transplantation Society

Barcelona, Spain,1996

8. Portal Vein Thrombendvenectomy at the Time of Liver Transplantation

Molmenti E; Roodhouse T; Jaiswal K; Jennings L; Casey D; Brooks B; Conkey A; Sanchez E; Mulligan D; Levy M; Goldstein R; Fasola C; Gonwa T;

Klintmalm G.

 XVIII International Congress of Transplant Society

Rome, Italy, 2000

9. Transplant Options for Hepatic Malignancies (Transplantation Versus Resection)

 Surgical Risk International Conference

San Antonio, Texas, 2000

10. The Use of Aprotinin in Orthotopic Liver Transplant Recipient Reduces the Operative

Abbas MA, Douglas DD, Frasco PE, Moss AA, Balan V, Rakela JL, Hentz JG, Mulligan DC

Southwestern Surgical Congress 53rd Annual Meeting

Cancun, Mexico,2001

11. Biliary Complications Associated with CMV Hepatitis in Orthotopic Liver

 Transplant Recipients

Harris EA, Koyfman S, Harrison ME, Douglas DD, Rakela JL, Balan V, Yousfi M, Moss AA, Mulligan DC Southwestern Surgical Congress 53rd Annual Meeting, Cancun, Mexico ,2001

12. Novel Imaging Modalities for Liver Resection and Living Donor Liver Transplantation

 International Symposium on Precision Liver Surgery

 Beiijing, People’s Republic of China,2011

13. Universities of Cambridge and Yale

 Transplant Education Meeting

 Trinity Hall, Cambridge, England 2016

14. Living Donor is Better than Marginal

 8th International Conference Living Donor Abdominal Organ Transplant

 Triste, Italy ,2016

15. How to Improve Outcome of LDLT for HCC

 International Symposium for Commemoration of 5000 LDLTS

 Asian Medical Center & Grand Walkerhill

 Seoul, Korea, 2018

16. Costs of Novel Technologies or Therapies

Transplant Education Meeting

University of Cambridge and Yale

Cambridge, UK, 2018

17. Bioengineering Techniques and Liver Transplantation

A-PHPBA 2019 7th Biennial Congress of the Asian-Pacific-Hepato-Pancreato-Biliary Association

 COEX (Convention and Exhibition Center)

 Seoul, South Korea, 2019

18. UNOS and Living Donation Present and Future of Donor Policies

10th International Conference: Living Donor Abdominal Organ Transplant

Gubbio, Italy ,2022

***National***

1. Amiodarone-Induced Thyrotoxicosis: Clinical Presentation and Expanded Indications for Thyroidectomy Fourteenth Annual Meeting of the American Association of Endocrine Surgeons

Williamsburg, Virginia 1993

2. Blood CMV PCR Detects CMV Infection Earlier Than Culture in Liver Transplant Recipients with CMV Disease: A Prospective Pilot Study

RK Sterling, FA Shiffrin, AB Post, PS Penmetsa, JA Schulak, CM Fasola, DC Mulligan, GH Jacobs, DGB Leonard, 1994

American Association for the Study of Liver Diseases

 Chicago, Illinois, 1994

3. Transplantation For Hepatocellular Carcinoma: A Comparison of Outcomes Between Patients Treated With Neoadjuvant Chemotherapy Pre-OLTX and Those With Incidental Hepatomas

David Mulligan, MD; Robert Goldstein, MD; Goran Klintmalm, MD, PhD, et al

45th Annual Meeting of the American Association for the Study of Liver Diseases

Chicago, Illinois

4. The Fate of Liver Offers Declined by a Single Center: A Study of 543 Cases

 David Mulligan, MD; Marlon Levy, MD; Goran Klintmalm, MD, PhD

45th Annual Meeting of the American Association for the Study of Liver Diseases

Chicago, Illinois, 1994

5. Can Anti-Hepatitis C Virus Seropositive Organs Safely Be Used in Liver Transplantation? David Mulligan, MD; Robert Goldstein, MD; Jeffrey Crippin, MD; Marwan Abouljoud, MD; Marlon Levy, MD; Bo Husberg, MD, PhD; Goran Klintmalm, MD, PhD

45th Annual Meeting of the American Association for the Study of Liver Diseases

Chicago, Illinois , 1994

6. Cyclosporine A-Based Immunosuppression in Liver Transplantation: Specific Patient Populations

David Mulligan, MD; Robert Goldstein, MD

Treatment Strategies in Liver Transplantation: Adjusting for Better Outcomes, American Association for the Study of Liver Diseases

Chicago, Illinois, 1994

7. Current Strategies of Immunosuppression in Solid Organ Transplantation

Upjohn National Symposium

Dallas, Texas, 1994

8. Should Liver Transplantation be Performed for Hepatitis B?

 Mulligan DC, MD; Klintmalm G, MD, PhD

Fifth ASTS Postgraduate Course

Chicago, Illinois, 1994

9. Hyperlipidemia After Liver Transplantation: A Randomized Trial of FK-506 Versus Cyclosporine

A Marwan Abouljoud, MD; Marlon Levy, MD; David Mulligan, MD; Bo Husberg, MD, PhD; Gonwa Thomas, MD; Jeffrey Crippin, MD; Goran Klintmalm, MD, PhD

20th Annual American Society of Transplant Physicians meeting

Chicago, Illinois, 1994

10. The Use of Anti-HCV Seropositive Organs in Liver Transplantation

David Mulligan, MD; Robert Goldstein, MD; Jeffrey Crippin, MD; Marwan Abouljoud, MD; Marlon Levy, MD; Bo Husberg, MD, PhD; Thomas Gonwa, MD; Goran Klintmalm, MD, PhD

Transplant Fellows Workshop

New Orleans, Louisiana, 1994

11. Outcome of Anti-Hepatitis C Virus Seropositive Organs in Patients Following Liver Transplantation

David Mulligan, MD; Robert Goldstein, MD; Goran Klintmalm, MD; et al

21st Annual Scientific Meeting of the American Society of Transplant Surgeons

Chicago, Illinois, 1995

12. Hepatitis C Viral Infection in Liver Transplantation: Effect of Cyclosporine A vs.

 FK506 David Mulligan, MD; Robert Goldstein, MD; Goran Klintmalm, MD,

PhD, et al American Society of Transplant Physicians, Scientific Sessions

Chicago, Illinois, 1995

13. Whole Blood Monitoring for FK506 Immunosuppression in Liver Transplantation:Imx vs. Enzyme Immunoassay

David Mulligan, MD: Robert Goldstein, MD: Goran Klintmalm, MD, PhD, et al

American Society of Transplant Physicians Scientific Sessions

Chicago, Illinois, 1995

14. Glutamate Dehydrogenase (GLDH) Fails as a Biochemical Marker for Acute Cellular Rejection in Liver Transplantation

GA Isenberg, RK Sterling, AB Post, GS Cooper, GH Jacobs, CM Fasola, DC Mulligan, JA Schulak , 1996

American Association for the Study of Liver Diseases

15. Endothelin Blockade Attenuates Hepatic Ischemia/Reperfusion Injury in the Rat

 48th Annual Meeting of the American Association for the Study of Liver Diseases

Chicago, Illinois, 1997

16. A Prospective Longitudinal Analysis of ATGAM Induction vs. Mycophenolate Mofetil Maintenance Immunosuppression for Orthotopic Liver Transplantation

American Society of Transplant Surgeons 24th Annual Scientific Meeting, 1998

27. Delayed Graft Function: State of the Art

 Panel presentation, consultant to Novartis

San Diego, California, 2000

28. The Effect of Orthotopic Liver Transplantation on the QTC Interval on Patients with End-Stage Liver Disease

Carey EJ, Douglas DD, Mulligan DC, Balan V, Harrison ME, Rakela JL American College of Gastroenterology

65th Annual Scientific meeting

New York, New York, 2000

29. Aprotinin Effects Blood Products Usage and Reoperative Rate for Bleeding Following Orthotopic Liver Transplantation

Abbas MA, Frasco PE, Rakela J, Harrison ME, Moss AA, Douglas DD, Balan V, Hentz J, Mulligan DC Transplant 2001 Annual Meeting

Chicago, Illinois, 2001

30. Biliary Complications Associated with Cytomegalovirus (CMV) Hepatitis in Orthotopic Liver Transplant (OLT) Recipients

Rodriguez-Davalos MI, Douglas DD, Huettl EA, Kasper DM, Harrison ME, Balan V, Moss AA, Yousfi M, Rakela JR, Mulligan DC

Transplant 2001 Annual Meeting

Chicago, Illinois, 2001

31. Living Donor and Split Liver Transplantation: How and Why?

2nd Annual Michigan Conference on Organ Donation- "New Frontiers in Organ Donation"

Dearborn, Michigan, 2005

32. Living Donor and Split Liver Transplantation: How & Why?

2nd Annual Michigan Conference on Organ Donation, New Frontiers in Organ Donation,

Dearborn, Michigan, 2005

33. Liver Advisory Board Meeting

Active discussion

Genzyme Corporation

Marina del Rey, California, 2005

34. Liver Transplantation

Grand Rounds

University of California Los Angeles

Los Angeles, California, 2005

35. To Preserve, or Not to Preserve the Middle Hepatic Vein: That Is the Question, Or Is It? Can We Better Define the Anatomy to Safely Divide the Liver for Successful Living Donor Liver Transplantation

Mulligan DC, Moss AA, Reddy KS, Esparra BC, Byrne T, Vargas H, Balan V, Douglas DD, Rakela J, Collins J.

American Transplant Congress Annual Meeting

Seattle, Washington, 2005

36. Leadership: Team Management and Organization

Panelist/speaker for pre-meeting symposium

American Transplant Congress Annual Meeting

Seattle, Washington, 2005

37. Solid Organ Transplantation for Donation After Cardiac Death Donors

Donor Network of Nevada, Organ Donation Collaborative

Las Vegas, Nevada, 2008

38. Surgical Complications in Liver Transplantation

 AST CAQ Review Course for Hepatologists

 Chicago, IL, 2008

36. Expanded Criteria Donors for Liver Transplantation

 UNOS Region 6 Forum

 Portland, Oregon, 2008

37. Donor Derived Infections

Optum Health – The 10th Annual Management of Transplantation and Complex Medical Conditions

 San Diego, CA, 2009

38. Innovations in Living Donor Kidney Transplantation

Optum Health Care Solutions

18th Annual National Clinical Conference

Chicago, IL, 2009

39. Indications for Liver Transplantation fo Metastatic Neuroendocrine Tumors

 North American Neuroendocrine Tumor Society Meeting

 Santa Fe, NM, 2010

40. Medical and Surgical Issues in DCD Transplantation

 American Transplant Congress

 San Diego, CA, 2010

41. Liver Transplantation Issues

 Plenary Presentation

 ASTS Winter Symposium

 Miami, FL, 2012

42. UNOS Regulatory Compliance: New Initiatives and Their Impact on the Transplant Community

 Business Practice Seminar

 ASTS Winter Symposium

 Miami, FL, 2012

43. American Society of Transplantation Surgeons (ASTS)

 ASTS 6th Annual Leadership Development Program

 Chicago, IL, 2015

44. The Yale-Cambridge Course on Transplantation: A Clinical and Translational Symposium

New York, New York, 2015

45. An Update on Broader Sharing Livers in the U.S.: Redistricting and National Review Board

 Mayo Clinic Priestley Society 52nd Annual Meeting

 Washington, DC, 2016

46. Changes in UNOS Policy for Liver/Kidney Allocation

 American Association for the Study of Liver Disease

 Boston, MA, 2016

47. Combined Liver-Kidney Transplantation: Ways to Continue Improve Outcomes

 American Transplant Congress

 Chicago, IL, 2017

48. Integrating Telemedicine into Health Care Delivery for the Transplant Population

 OPTUM Health Education

 Chicago, IL, 2017

49. The Ecosystem of Transplantation

 ASTS 8th ASTS Leadership Development Program

 Northwestern University

 Evanston, IL, 2018

50. Transplant Surgeon Perspective | Moderator

 8th ASTS Leadership Development Program

 Northwestern University Kellogg School

 Chicago, IL, 2018

51. Collaboration Uterine Transplant

 OPTUM Health Education

 Dallas, TX, 2018

52. The Future is Now: Saving More Lives Through Transplantation | Moderator

 ASTS 17th Annual State of the Art Symposium

 Miami, FL, 2018

53. The Modern Transplant Surgeon: Striking the Right Balance

 ASTS Winter Symposium

 Miami, FL, 2019

54. The Case for Robotic Surgery

 Yale Liver Cancer Symposium

 Yale University- West Campus

 New Haven, CT, 2019

55. Organ Supply

 Uterus Transplant Symposium

 Baylor University Medical Center

 Dallas, TX, 2019

56. Liver Transplantation | Moderator

 The Society for Surgery of the Alimentary Tract (SSAT) 60th Annual Meeting

 San Diego, CA, 2019

57. OPTN/UNOS Leadership Update on Policies and Plans

 UNOS Region 8

 Kansas City, KS, 2019

58. Wellness Amidst the Chaos

 Memorial Sloan Kettering Annual Trumbull Lectureship

 New York, NY, 2019

59. OPTN/UNOS Leadership Update on Policies and Plans

 UNOS Region 5

 San Diego, CA, 2020

60. OPTN/UNOS Leadership Update on Policies and Plans

 UNOS Region 10

 Virtual due to COVID-19, 2020

61. OPTN/UNOS Leadership Update on Policies and Plans

 UNOS Region 11

 Virtual due to COVID-19, 2020

62. OPTN/UNOS Modifications in Policy for COVID-19

 NY State Transplantation Council

 Virtual due to COVID-19, 2020

63. COVID-19 and the Liver: Reentry and Return to the Pre-Pandemic State-

AASLD

 Webinar, 2020

64. OPTN/UNOS Leadership Update on Policies and Plans

 UNOS Region 3

 Virtual due to COVID-19, 2020

65. OPTN/UNOS Leadership Update on Policies and Plans

 UNOS Region 7

 Virtual due to COVID-19, 2020

66. The Role of TIPS Prior to Non-Transplant Surgery

ALTA in ALTA Consensus Conference in the Use of TIPS for the Management of Portal Hypertension

 Virtual due to COVID-19, 2020

67. Welcoming Remarks Presentation and UNOS Update

 ASTS 21st Annual State of the Art Winter Symposium

 Virtual, 2021

68. OPTN Update - General Session

 UNOS Region 4

 Virtual due to COVID-19, 2021

69. OPTN Update – Executive Committee / 2021-2024 OPTN Strategic Plan

 UNOS Region 4

 Virtual due to COVID-19, 2021

70. OPTN Update – Executive Committee / 2021-2024 OPTN Strategic Plan

 UNOS Region 3

 Virtual due to COVID-19, 2021

71. OPTN Update – Executive Committee / 2021-2024 OPTN Strategic Plan

 UNOS Region 5

 Virtual due to COVID-19, 2021

72. Governing Board Task Forces / COVID-19 Task Force

 AASLD Governing Board

 Virtual, 2021

73. OPTN Update – Executive Committee / 2021-2024 OPTN Strategic Plan

UNOS Region 1

Virtual due to COVID-19, 2021

74. Mission Driven5/2021 Journals Publication - Hepatology Communications Editor-in-Chief Search Committee

 AASLD Governing Board

 Virtual, 2022

 75. Innovation to Deliver High – Quality Care to the Communities We Serve – Moderator

UNOS Transplant Management Forum

 Phoenix, Arizona, 2022

76. American Surgical Association Annual Meeting

 Chicago, IL, 2022

77. OPTN Board of Directors Meeting

 UNOS

 Richmond, VA, 2022

78. American Transplant Congress Annual Meeting

 Boston, MA, 2022

79. Business Practice and Advocacy Session

 OPTN/ UNOS Update

American Society of Transplant Surgeons Annual Meeting

 Miami, FL, 2022

***Regional***

1. Ethical Issues in Transplantation

Arizona Osteopathic Medical Association 20th Fall Seminar

Tucson, Arizona, 2000

2. A Novel Antioxidant Enzyme and Its Role in Ischemia-Reperfusion Injury

Backhaus RA, Lille S, Mulligan DC

Southwest Regional BioPartnering Expo

Tempe, Arizona, 2001

3. Case Study: Living Donor vs Cadaveric OL Transplantation

Fujisawa Ronald W. Busuttil Transplant Fellows Symposium,

Fairmont Scottsdale Princess Scottsdale, Arizona, 2002

4. Personal Experiences in Medicine

National Youth Leadership Forum on Medicine

Phoenix, Arizona, 2005

5. Treatment Options for Cancers of the Liver

Cancer Registry Association of Arizona

Arizona, 2006

6. Living Donor Liver Transplantation in the Mayo System

Mayo Winter Gastroenterology Meeting: Gastroenterology Linked to

Endoscopy and Hepatology 2006

Scottsdale, Arizona, 2006

7. Care of Transplant Patients for the Hospitalist

Mayo Clinic Update in Hospital Medicine

Tucson, Arizona, 2007

8. Leadership in Medicine

National Youth Forum

Phoenix, Arizona, 2008

9. Liver Allocation/Distribution & National Liver Review Board

 American Liver Foundation

 Hamden, CT, 2015

10. Organ Transplant – Need for Donors

 Facebook Interview

 WTNH,2020

New Haven, CT

11. Metabolic DM/Obesity Mediated HCC – Moderator

Yale Primary Liver Cancer Summit

Virtual, 2020

12. The Importance of Wearing a Mask for the Sake of Immunocompromised Patients

 WTNH Interview

 Virtual, 2020

13. How Well do COVID Vaccines Protect After Organ Transplantation

 WTNH Interview

 Virtual, 2021

14. Living Donor Liver Transplant Virtual Workshop

 Yale-New Haven Hospital

 Center for Living Organ Donors

 Virtual, 2021

15. Liver Transplant Activities at YNHH

 American Liver Foundation Re-birthday Celebration

 Virtual, 2021

**INVITED PRESENTATIONS AND VISITING PROFESSORSHIPS**

***Invited Presentations***

1. Surgical Complications in Liver Transplantation

AST CAQ Review Course for Hepatologists,

Chicago, Illinois, 2006

2. Outcome of Solid Organ Transplantation Using Various Preservation Solutions

Transplant Grand Rounds, Loma Linda University,

Loma Linda, California, 2007

3. Liver Surgery and Transplantation

Surgical Grand Rounds, Maricopa County Medical Center

Phoenix, Arizona, 2007

4. Liver Surgery and Transplantation

Midwestern Medical School,

Phoenix, Arizona, 2007

5. Surgical Complications in Liver Transplantation

AST CAQ Review Course for Hepatologists,

Chicago, Illinois, 2008

6. Organ Preservation Solutions - Mayo Clinic Arizona Experience

UNOS Region 6 Forum,

Portland, Oregon, 2008

7. Expanded Criteria Donors for Liver Transplantation

UNOS Region 6 Forum,

Portland, Oregon, 2008

8. Innovations in Living Donor Kidney Transplantation

Optum Health Care Solutions' 18th Annual National Clinical Conference

Chicago, Illinois, 2009

9. Town Hall on Health Care Reform

The Arizona Republic,

Phoenix, Arizona, 2009

10. Allocation Issues in Liver Transplantation in the US

Transplant Grand Rounds Mayo Clinic

Rochester, Minnesota, 2009

11. Donor Derived Infections

Optum Health's, The 10th Annual Management of Transplantation and Complex Medical Conditions,

San Diego, California, 2009

12. Living Donor Liver Transplantation: The Mayo Clinic Arizona Experience

Transplant Grand Rounds

Baylor University Medical Center,

Dallas, Texas, 2009

13. Indications for Liver Transplantation for Metastatic Neuroendocrine Tumors

North American Neuro Endocrine Tumor Society Meeting

Santa Fe, New Mexico, 2010

14. Medical and Surgical Issues in DCD Transplantation

American Transplant Congress

San Diego, California, 2010

15. Liver Re-Transplantation Issues

Plenary Presentation

ASTS Winter Symposium

Miami, Florida, 2012

16. UNOS Regulatory Compliance: New Initiatives and Their Impact on the Transplant Community

Business Practice Seminar

ASTS Winter Symposium

Miami, Florida, 2012

17. American Association for the Study of Liver Diseases (AASLD)

 Vision: To Prevent and Cure Liver Disease

Washington, DC, 2013

18. American Society of Transplant Surgeons (ASTS)

 ASTS State of the Art Winter Symposium: Meeting the Challenges of Innovation

Miami, Florida, 2014

19. 2014 Controversies in Transplantation

 University of Colorado, Anschutz Medical Campus

 Breckenridge, CO, 2014

20. Digestive Diseases Week 2014 (DDW2014)

American Association for the Study of Liver Disease

Washington, DC, 2014

21. Keynote: Highlight: 3D Printing and Organ Transplantation-Where Are We?

UMiami – Advances in Heptobiliary Diseases and Liver Transplantation 2020 Update XXIII

 Virtual Conference, 2020

22. Welcome Presentation & UNOS Update

 ASTS Winter Symposium

 Digital Format, 2021

23. Simultaneous Liver Kidney Transplant: How Did We Do with the New Criteria? UNOS Perspective

 AASLD – Liver Meeting

 Webinar, 2021

24. Presidents Address

 UNOS Transplant Management Forum

 Virtual, 2021

25. Policy and Regulation: Research, UNOS/OPTN

FASEB Transplant Genomics: Ethics of Research and Clinical Applications

 Virtual, 2021

26. Solid Organ Transplantation in the United States: System and Clinical Challenges and the Implications for Organ Recipient Functioning

 National Academies of Sciences, Engineering, and Medicine

 Virtual, 2021

27. How well COVID-19 Vaccines Protect after an Organ Transplant

 VuMedi

 Presented a short video over zoom, 2021

28. President’s Address

 29th Annual UNOS Transplant Management Forum (TMF)

 Virtual, 2021

29. Strategic Plan

 UNOS Board Policy Group

 Virtual, 2021

30. UNOS/OPTN Updates: Moving Through the Pandemic into the Future

University of Wisconsin, Division of Transplantation Grand Rounds

Virtual, 2021

31. Minimal Invasive Surgery in Living Donor Liver Transplantation (Moderator)

 American Transplant Congress

 Virtual, 2021

32. Updates in Transplantation and Allocation

 Southern Surgeons Club Conference

 Yale University, New Haven, 2022

**Visiting Professorships**

1. Regional Variation Under MELD Allocation in the U.S.

UCLA Medical Center, Surgical Grand Rounds

Los Angeles, California, 2005

2. Liver Transplantation

 University of California

 Los Angeles, California, 2005

3. Liver Surgery and Transplantation

 Midwestern Medical School

 Phoenix, Arizona, 2007

4. Living Donor Liver Transplantation at Mayo Clinic Arizona

California Pacific Medical Center Transplant Surgery Grand Rounds

San Francisco, California, 2007

5. Liver Surgery and Transplantation

 Surgical Grand Rounds

 Maricopa County Medical enter

 Phoenix, Arizona, 2007

6. Outcomes of Solid Organ Transplantation Using Various Preservation

 Solutions

 Transplant Grand Rounds

 Loma Linda University

 Loma Linda, California, 2007

7. Surgical Techniques for Liver Resections and Transplantation

Surgical Grand Rounds Maricopa County Medical Center

Phoenix, Arizona, 2008

8. Living Donor Liver Transplantation: The Mayo Clinic Arizona

 Experience

 Transplant Grand Rounds

 Baylor University Medical Center

 Dallas, Texas, 2009

9. Resection Versus Living Donor Liver Transplantation for HCC

Meet the Professor Presentation

American Association of Liver Diseases Annual Congress

Boston, Massachusetts, 2009

10. Risk of Infection Transmission from Solid Organ Transplantation

Transplant Grand Rounds Mayo Clinic,

Rochester, Minnesota, 2009

11. Current Issues in Liver Allocation in the United States

Visiting Professor and Surgical Grand Rounds

Yale University School of Medicine,

New Haven, Connecticut, 2011

12. Novel Imaging in Liver Surgery and Living Donor Transplantation

Visiting Professor and Surgical Grand Rounds

Yale University School of Medicine,

New Haven, Connecticut, 2011

13. Novel Imaging Modalities for Liver Resection and Living Donor Liver Transplantation

 International Symposium on Precision Liver Surgery

 Beiijing, People’s Republic of China, 2011

14. Liver Imaging for Living Donor Liver Transplantation and Resection

 Precision Liver Surgery Symposium

 Beijing, People’s Republic of China, 2012

15. Liver Allocation

 Aurora Health Care

 Milwaukee, Wisconsin, 2015

16. Liver Allocation

 Harvard Medical School

 Massachusetts General Hospital

 Boston, Massachusetts, 2015

17. Annual Lisa Short, PharmD and Tyler Short Lectureship

 University of Louisville

 Department of Surgery Grand Rounds

 Louisville, Kentucky, 2015

18. Liver Allocation

 Visiting Professor and Surgical Grand Rounds

 St. Luke’s Medical Center

 Milwaukee, Wisconsin, 2016

19. American Association for the Study of Liver Disease

 Liver Transplantation in the High MELD Era: Perioperative Management of the Critically Ill Patient

 Boston, Massachusetts, 2016

20. Yale University Live Update 2016

 Liver Cancer: The Role of Liver Transplantation

 New Haven, Connecticut, 2016

21. Living Donor is Better than Marginal

 8th International Conference Living donor Abdominal Organ Transplant

 Triste, Italy, 2016

22. Update on Liver Allocation and Distribution

 Grand Rounds

 University of Wisconsin-Madison

 Madison, Wisconsin, 2017

23. St. Francis Hospital and Medical Center

 Living donor Liver Transplantation – where are we now?

 Grand Rounds

 Hartford, Connecticut, 2017

24. University of Illinois at Chicago

 Challenges in Implementing Liver Paired Exchange

 Chicago, Illinois, 2018

25. University Hospital Cleveland Medical Center

 Celebrate UH Transplant Institute’s – 50 Years of Innovation and Success

 Cincinnati, Ohio, 2018

26. How to Improve Outcome of LDLT for HCC

 International Symposium for Commemoration of 5000 LDLTS

 Asian Medical Center & Grand Walkerhill

 Seoul, Korea, 2018

27. May Clinic Arizona Transplant Center

 Work Live Balance. How We Got Here and Built the Program

 How We Achieve Work Life Balance

 Phoenix, Arizona, 2019

28. Bioengineering Techniques and Liver Transplantation

A-PHPBA 2019 7th Biennial Congress of the Asian-Pacific-Hepato-Pancreato-Biliary Association

 COEX (Convention and Exhibition Center)

 Seoul, South Korea, 2019

**Professional Service**

1994 XVth World Congress of the Transplantation SocietyPoster Workshop on Liver Transplantation, Chair

1995- 1998 Ohio Solid Organ Transplantation Consortium

Liver Transplantation Selection Committee, MemberResearch Committee, MemberSmall Bowel Transplantation Selection Committee, MemberPhi Delta Epsilon Medical Fraternity, Member

1996- 1998 American Liver Foundation, Northern Ohio Chapter

 Board of Directors, Member

1996- Present American Association for the Study of Liver Diseases

1996 - Present Program Education Committee, Member

1997-1998 Medical Advisory Committee, Chair1997- 1998 Membership Committee, Chair

1998-2001 Liver Transplantation and Surgery Committee, Member

2006-2009 Annual Meeting, Abstract Reviewer

2006-2009 Abstract Review Committee: Cell Transplantation, Member

2006-2009 Abstract Review: Immunology, Member

2006-2009 Abstract Review: Preservation, Ischemia/Reperfusion, Member

2009-Present Abstract Review Committee

 Experimental Liver Transplantation

 Cellular Immunology, Preservation and Cell Transplantation, Chair

2012-2015 Liver Transplantation and Surgery Special Interest Group, Chair; Membership and Committee Member

2018-Present Governing Board, Member-At-Large (2018-Present);

2019 Surgeon Representative to the Board of Governors

2020-Present Research Subcommittee-COVID-19 Task Force, Chair

2020-Present COVID-19 Task Force

2000-Present American College of Surgeons, Fellow, Oncology Group, Member

1997-Present American Society of Transplant Surgeons, Member

2003-2006Membership Committee, Chair

2006-2009 Standards on Organ Transplantation Committee, Chair

2010-2013 Councilor

2015-2017 Business Practice Services Committee, Co-Chair

2017-Present Business Practices Services Committee, Chair

2020 COVID-19 Task Force

1997- Present American Hepato-Pancreato-Biliary Associate**,** Member

1997-1998 Lifebanc**,** Associate Medical Director

1998-Present International Liver Transplantation Society, Member

1998-Present Society for Surgery of the Alimentary Tract, Member

1999-2013 Arizona Medical Association, Member

 Arizona Save-A-Life Alliance Board of Directors Member

 Case Western Reserve University

 Department of Surgery

 Resident Selection Committee Member

 University Hospitals of Cleveland

 Chemotherapy Credentialing Subcommittee Member

 Ireland Cancer Center

 Taskforce on Management of Hepatic Malignancies Chair

 Medication Use and Assessment Improvement Subcommittee Member

Patient Care Operating Support System (PCOSS) Physician Steering Committee Member

1999-2002 Phoenix Surgical Society, Member

1999-Present European Society for Organ Transplantation, Member

2000 –2013 Donor Network of Arizona, Board of Directors**,** Member

1999 –2013 Medical Advisory Board Member

1999-Present United Network of Organ Sharing / Organ Procurement and Transplantation Network (UNOS/OPTN)

2019-2020 President Elect/Vice Chair

2020-2021 President

2021-2022 Immediate Past President

1999-Present United Network of Organ Sharing Organ Procurement and Transplantation Network (UNOS/OPTN)

1999-Present Voting Member

1999-2001 Region Review Board, Member

2001-2004 Region Review Board, Chair

2001-2004 Membership and Professional Standards Committee Region 5 Representative,

2001-2004 Region Review Board, Chair

2004-2005 Liver and Intestinal Organ Transplant Committee, Representative-At-Large

2004-2006 Membership and Professional Standards Committee, Member-At-Large

2004-2006 Region 5 Associate Counselor

2005-2009 Workgroup for Organ Acceptance, Chair

2006-2008 Board of Directors, Region 5, Representative

2006-2008 Region 5 Counselor

2009-Present Organ Procurement and Transplantation Network (OPTN)

2009-2011 Membership and Professional Standards Committee, Vice Chair

2009-Present Workgroup for Organ Acceptance, Composite Pre-Transplant Metric (CPM) Workgroup, Chair

2011-2013 Liver and Intestinal Organ Transplant Committee, Vice Chair

2011-2013 Policy and Oversight Committee, LIT Representative

2013-2015 Liver and Intestinal Organ Transplant Committee, Chair

2016-2019 Advisory Council on Transplantation to the Secretary of HHS, Chair

2015-2016 Liver and Intestinal Organ Transplant Committee, Immediate Past Chair

2019-Present Nominations Committee, Chair

2019 Business Practices Committee, Chair

2010-Present American Surgical Association Member

2021 The National Academies of Sciences, Engineering and Medicine,

External Reviewer

***Journals:***

2004-2009 Associate Editor, *Liver Transplantation*

2004-Present Editorial Board Member, *Liver Transplantation*

2004-Present Reviewer, *American Journal of Transplantation*

2005 Publishing Editor, *Current Opinion in Organ Transplantation*

Reviewer:

2020-2022 Reviewer, *JAMA*

2020-2022 Reviewer, *Nature*

2013-2021 Reviewer, *Hepatology*

2013-2021 Reviewer, *Transplantation*

2005 Reviewer, Section on Organ Preservation and Procurement: (Vol 10, No. 2, June 2005) *Current Opinion in Organ Transplantation*

2004-Present Reviewer, *American Journal of Transplantation*2004 - Present Reviewer, *Digestive Diseases and Sciences*2003 - Present Reviewer, *Journal of Gastrointestinal Surgery*

***University Committees***

2015 - Present Clinical Advisory Board (CAB), Member

2016 – Present Joint Leadership Committee (JLC), Member

2017 – Present Appointments and Promotions Committee, Member

2017 – Present Yale Medicine Executive Leadership Development Program

2018 – Present Academy of Communication in Healthcare Relationship Centered Communication

2020 – Present Joint Council and Operations Council (JCOC)

**BIBLIOGRAPHY:**

***Peer-reviewed Articles***

* + - 1. Levy MF, Goldstein RM, Husberg BS, Gonwa TA, Backman L, Abouljoud M, **Mulligan D**, Klintmalm GB. Baylor update: outcome analysis in liver transplantation. Clin Transpl. 1993; 161-73.
			2. **Mulligan DC**, McHenry CR, Kinney W, Esselstyn CB. Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy. Surgery. 1993 Dec; 114(6):1114-9. PMID:8256216.
			3. Holmberg S, Levy M, Goldstein R, Husberg B, **Mulligan DC**, Gonwa T, Brooks B, Jennings L, Klintmalm G. Lymphoma after liver transplantation - a single center clinical and epidemiological experience. Swedish Journal of Medicine. 1994.
			4. Abouljoud MS, Levy MF, Rees CR, Diamond NG, Lee SP, **Mulligan DC**, Goldstein RM, Husberg B, Gonwa TA, Klintmalm GB. A comparison of treatment with transjugular intrahepatic portosystemic shunt or distal splenorenal shunt in the management of variceal bleeding prior to liver transplantation. Transplantation. 1995 Jan 27; 59(2):226-9. PMID:7839445.
			5. **Mulligan DC**, Goldstein RM, Crippin JS, Abouljoud MS, Levy MF, Husberg BS, Gonwa TA, Foster BR, Tillery GW, Klintmalm GB. Use of anti-hepatitis C virus seropositive organs in liver transplantation. Transplant Proc. 1995 Feb; 27(1):1204-5. PMID:7878850.
			6. Levy MF, Jennings L, Abouljoud MS, **Mulligan DC**, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. Quality of life improvements at one, two, and five years after liver transplantation. Transplantation. 1995 Feb 27; 59(4):515-8. PMID:7878756.
			7. **Mulligan DC**, Klintmalm GB. Should liver transplantation be performed for hepatitis B? Clin Transplant. 1995 Jun; 9(3 Pt 2):246-8. PMID:7670170.
			8. **Mulligan D**, Gentry L, Dombrausky L, Klintmalm G, Nikaein A. Monitoring of allograft recipients for the development of HLA-specific antibodies: elimination of OKT3 as a complicating factor. Clin Transplant. 1995 Dec; 9(6):438-41. PMID:8645885.
			9. Schulak JA, **Mulligan DC**, Robinson A. Intrathymic spleen cell inoculation and ALS fails to induce tolerance to rat pancreas allografts. Transplant Proc. 1997 Feb-Mar; 29(1-2):1070-1. PMID:9123203.
			10. Schulak J, May E, Post A, Fasola C, **Mulligan D**, Sterling R. Reduction of early rejection in adult liver transplantation with ATG induction therapy. Transplant Proc. 1997 Feb-Mar; 29(1-2):555-6. PMID:9123126.
			11. Ghandour FZ, Knauss TC, **Mulligan DC**, Schulak JA, Hricik DE. Influence of steroid withdrawal on proteinuria in renal allograft recipients. Clin Transplant. 1997 Oct; 11(5 Pt 1):395-8. PMID:9361929.
			12. Harwell CM, Newman LN, Cacho CP, **Mulligan DC**, Schulak JA, Friedlander MA. Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis. Perit Dial Int. 1997 Nov-Dec; 17(6):586-94. PMID:9655159.
			13. Chitale AA, Sterling RK, Post AB, Silver BJ, **Mulligan DC**, Schulak JA. Resolution of spur cell anemia with liver transplantation: a case report and review of the literature. Transplantation. 1998 Apr 15; 65(7):993-5. PMID:9565106.
			14. Post AB, **Mulligan DC**, Bush W. Cost analysis of four strategies for prevention of CMV infection in liver transplant recipients. Transplant Proc. 1998 Aug; 30(5):2102-3. PMID:9723406.
			15. Molmenti EP, Roodhouse TW, Jaiswal K, Jennings LW, Sanchez EQ, Marubashi S, Jung G, Brooks BK, Conkey A, **Mulligan DC**, Levy MF, Goldstein RM, Klintmalm GB. Portal vein thrombendvenectomy in cases of organized portal vein thrombosis at the time of liver transplantation. Transplantation. 2000 Apr; 69(8):Suppl S, 242.
			16. Abbas MA, **Mulligan DC**, Ramzan NN, Blair JE, Smilack JD, Shapiro MS, Lidner TK, Olden KW. Colonic perforation in unsuspected amebic colitis. Dig Dis Sci. 2000 Sep; 45(9):1836-41. PMID:11052328.
			17. Lille ST, Lefler SR, Mowlavi A, Suchy H, Boyle EMJr, Farr AL, Su CY, Frank N, **Mulligan DC**. Inhibition of the initial wave of NF-kappaB activity in rat muscle reduces ischemia/reperfusion injury. Muscle & Nerve. 2001 Apr; 24(4):534-41. PMID:11268026.
			18. **Mulligan DC**. Resection vs. Transplantation for Hepatocellular Carcinoma. Audio-Digest Gastroenterology. 2001 Jul; 15(7).
			19. Abbas MA, Collins JM, **Mulligan DC**. Renal cell carcinoma metastatic to pancreas. Am J Surg. 2001 Aug; 182(2):183-4. PMID:11574093.
			20. Molmenti EP, Roodhouse TW, Molmenti H, Jaiswal K, Jung G, Marubashi S, Sanchez EQ, Gogel B, Levy MF, Goldstein RM, Fasola CG, Elliott EE, Bursac N, **Mulligan D**, Gonwa TA, Klintmalm GB. Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. Ann Surg. 2002 Feb;235(2):292-6. PMID:11807371. PMCID:1422428.
			21. Hellinger WC, Yao JD, Alvarez S, Blair JE, Cawley JJ, Paya CV, O'Brien PC, Spivey JR, Dickson RC, Harnois DM, Douglas DD, Hughes CB, Nguyen JH, **Mulligan DC**, Steers JL. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation. 2002 Jun 27; 73(12):1904-9. PMID:12131685.
			22. Vargas HE, Laskus T, Radkowski M, Wilkinson J, Balan V, Douglas DD, Harrison ME, **Mulligan DC**, Olden K, Adair D, Rakela J. Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl. 2002 Nov; 8(11):1014-9. PMID:12424714.
			23. Lefler SR, Lille ST, Huemer G, Tucker R, Murray T, Schoeller T, **Mulligan DC**. Activation time course of activator protein-1 and effect of proline dithiocarbamate during ischemia-reperfusion in rat skeletal muscle. Ann Plast Surg. 2002 Dec; 49(6):654-9. PMID:12461450.
			24. Lefler SR, St Peter SD, Rodriguez-Davalos MI, Perumean JC, Spence NA, Moss AA, **Mulligan DC**. Amelioration of hepatic ischemia/reperfusion injury using indolepropionic acid. Transplant Proc. 2002 Dec; 34(8):3065-6. PMID:12493376.
			25. St Peter SD, Nguyen CC, **Mulligan DC**, Moss AA. Subcutaneous metastasis at a surgical drain site after the resection of pancreatic cancer. International Journal of Gastrointestinal Cancer. 2003; 33(2-3):111-5. PMID:14716058.
			26. St Peter SD, Moss AA, **Mulligan DC**. Effects of tacrolimus on ischemia-reperfusion injury. Liver Transpl. 2003 Feb; 9(2):105-16. PMID:12548502.
			27. St Peter SD, Post DJ, Rodriguez-Davalos MI, Douglas DD, Moss AA, **Mulligan DC**. Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation. Liver Transpl. 2003 Feb; 9(2):144-9. PMID:12548508.
			28. Wiesner RH, Rakela J, Ishitani MB, **Mulligan DC**, Spivey JR, Steers JL, Krom RAF. Recent advances in liver transplantation. Mayo Clin Proc. 2003 Feb; 78(2):197-210. PMID:12583530.
			29. Blair JE, Douglas DD, **Mulligan DC**. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis. 2003 Mar; 5(1):3-8. PMID:12791068.
			30. St Peter SD, Moss AA, Huettl EA, Leslie KO, **Mulligan DC**. Chemoembolization followed by orthotopic liver transplant for epithelioid hemangioendothelioma. Clin Transplant. 2003 Dec; 17(6):549-53. PMID:14756273.
			31. Sharma P, Perri RE, Sirven JE, Zeldenrust SR, Brandhagen DJ, Rosen CB, Douglas DD, **Mulligan DC**, Rakela J, Wiesner RH, Balan V. Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transpl. 2003 Dec; 9(12):1273-80. PMID:14625827.
			32. Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, **Mulligan D**, Rakela J, Douglas DD. Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci. 2004 Jan; 49(1):38-41. PMID:14992432.
			33. Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, **Mulligan D**, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transpl. 2004 Jan; 10(1):36-41. PMID:14755775.
			34. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, **Mulligan D**, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004 Jan 27; 77(2):190-4. PMID:14742979. DOI:10.1097/01.TP.0000100481.14514.BB.
			35. Carey EJ, Douglas DD, Balan V, Vargas HE, Byrne TJ, Moss AA, **Mulligan DC**. Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: a single-center experience. Liver Transpl. 2004 Apr; 10(4):529-33. PMID:15048796. DOI:10.1002/lt.20127.
			36. **Mulligan DC**, Reddy KS, Moss AAJr. New preservation solutions for use in liver transplantation. Current Opinion in Organ Transplantation. 2004 Jun; 9(No 2):159-62.
			37. Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib A, Fasola C, Adair D, Radkowski M, Kibler KV, Nowicki M, Douglas D, Williams J, Netto G, **Mulligan D**, Klintmalm G, Rakela J, Vargas HE. Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. J Infect Dis. 2004 Jun 1; 189(11):2037-46. PMID:15143471.
			38. St Peter S, Rodriquez-Davalos MI, Rodriguez-Luna HM, Harrison EM, Moss AA, **Mulligan DC**. Significance of proximal biliary dilatation in patients with anastomotic strictures after liver transplantation. Dig Dis Sci. 2004 Aug; 49(7-8):1207-11. PMID:15387348.
			39. Rodriguez-Luna H, Balan V, Sharma P, Byrne T, **Mulligan D**, Rakela J, Vargas HE. Hepatitis C virus infection with hepatocellular carcinoma: Not a controversial indication for liver transplantation. Transplantation. 2004 Aug 27; 78(4):580-3. PMID:15446318.
			40. Wiesner RH, Freeman RB, **Mulligan DC**. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology. 2004 Nov; 127(5 Suppl 1):S261-7. PMID:15508092.
			41. Faybush E, **Mulligan DC**, Birch BD, Sirven JI, Balan V. Liver transplant in a patient with a ventriculoperitoneal shunt. Liver Transpl. 2005 Apr; 11(4):467-8. PMID:15776410.
			42. Heilman RL, Mazur MJ, Reddy KS, Moss A, Post D, **Mulligan D**. Steroid avoidance immunosuppression in low-risk kidney transplant recipients. Transplant Proc. 2005 May; 37(4):1785-8. PMID:15919466.
			43. Frasco PE, Poterack KA, Hentz JG, **Mulligan DC**. A comparison of transfusion requirements between living donation and cadaveric donation liver transplantation: relationship to model of end-stage liver disease score and baseline coagulation status. Anesth Analg. 2005 Jul; 101(1):30-7, table of contents. PMID:15976201.
			44. Orrego M, Guo LS, Reeder C, De Petris G, Balan V, Douglas DD, Byrne T, Harrison E, **Mulligan D**, Rodriguez-Luna H, Moss A, Reddy K, Rakela J, Vargas HE. Hepatic B-cell non-Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection. Liver Transpl. 2005 Jul; 11(7):796-9. PMID:15973702.
			45. Rodriguez-Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, **Mulligan D**. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transplant. 2005 Sep; 5(9):2244-7. PMID:16095504.
			46. Guo L, Orrego M, Rodriguez-Luna H, Balan V, Byrne T, Chopra K, Douglas DD, Harrison E, Moss A, Reddy KS, Williams JW, Rakela J, **Mulligan D**, Vargas HE. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl. 2006 Apr; 12(4):560-5. PMID:16555313. DOI:10.1002/lt.20660.
			47. Sachdev M, Hernandez JL, Sharma P, Douglas DD, Byrne T, Harrison ME, **Mulligan D**, Moss A, Reddy K, Vargas HE, Rakela J, Balan V. Liver transplantation in the MELD era: a single-center experience. Dig Dis Sci. 2006 Jun; 51(6):1070-8. PMID:16865573. DOI:10.1007/s10620-006-8011-1.
			48. Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, **Mulligan DC**. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc. 2006 Jun; 38(5):1307-13. PMID:16797289. DOI:10.1016/j.transproceed.2006.02.116.
			49. Sharma P, Harper AM, Hernandez JL, Heffron T, **Mulligan DC**, Wiesner RH, Balan V. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant. 2006 Aug; 6(8):1957-62. Epub 2006 Jun 09. PMID:16771808. DOI:10.1111/j.1600-6143.2006.01411.x.
			50. Fallon MB, **Mulligan DC**, Gish RG, Krowka MJ. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl. 2006 Dec; 12(12 Suppl 3):S105-7. PMID:17123282. DOI:10.1002/lt.20971.
			51. Krowka MJ, Fallon MB, **Mulligan DC**, Gish RG. Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transpl. 2006 Dec; 12(12 Suppl 3):S114-6. PMID:17123283. DOI:10.1002/lt.20975.
			52. \*Pasha SF, Blair JE, Garvey PB, Gray RJ, **Mulligan DC**, Collins JM, Heigh RI. Hemosuccus Pancreaticus in the Era of Capsule Endoscopy and Double Balloon Enteroscopy Complicated by Multifocal Mycobacterium chelonae/abscessus Infection. Case Rep Gastroenterol. 2007; 1(1):38-47 Epub 2007 Aug 7. PMID:21487470. PMCID:3073786. DOI:10.1159/000104977.
			53. Blair JE, **Mulligan DC**. Coccidioidomycosis in healthy persons evaluated for liver or kidney donation. Transpl Infect Dis. 2007 Mar; 9(1):78-82. PMID:17313480.
			54. Cheruvattath R, Balan V, Stewart R, Heilman RL, **Mulligan DC**, Kusne S. Kluyvera co-infection in two solid organ transplant recipients: an emerging pathogen or a colonizer bystander? Transpl Infect Dis. 2007 Mar; 9(1):83-6. PMID:17313481.
			55. Sachdev MS, Blair JE, **Mulligan DC**, Kusne S. Coccidioidomycosis masked by symptoms of end-stage liver disease in transplant candidates. Transpl Infect Dis. 2007 Jun; 9(2):153-5. PMID:17462003.
			56. \*Pasha SF, Harrison ME, Das A, Nguyen CC, Vargas HE, Balan V, Byrne TJ, Douglas DD, **Mulligan DC**. Endoscopic treatment of anastomotic biliary strictures after deceased donor liver transplantation: outcomes after maximal stent therapy. Gastrointest Endosc. 2007 Jul; 66(1):44-51. PMID:17591473. DOI:10.1016/j.gie.2007.02.017.
			57. Mekeel KL, Mazur MJ, Reddy KS, **Mulligan DC**, Heilman RL, Chakkera HA, Andrews PE, Moss AA. Diffuse parenchymal urine leak after kidney transplantation following degloving injury during donor nephrectomy. Am J Transplant. 2007 Aug; 7(8):2039-41. Epub 2007 Jun 18. PMID:17578504. DOI:10.1111/j.1600-6143.2007.01870.x.
			58. Mekeel K, **Mulligan D**, Reddy KS, Moss A, Harold K. Laparoscopic incisional hernia repair after liver transplantation. Liver Transpl. 2007 Nov; 13(11):1576-81. PMID:17969189. DOI:10.1002/lt.21290.
			59. Heilman RL, Chakkera HA, Reddy KS, Colby TV, Moss AA, Williams JW, Mazur MJ, Petrides S, **Mulligan DC**. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression. Clin Transplant. 2008 May-Jun; 22(3):309-15. PMID:18482051. DOI:10.1111/j.1399-0012.2007.00786.x.
			60. Mekeel KL, Moss AA, Reddy KS, Douglas DD, Vargas HE, Carey EJ, Byrne TJ, Harrison ME, Rakela J, **Mulligan DC**. Living donor liver transplantation in polycystic liver disease. Liver Transpl. 2008 May; 14(5):680-3. PMID:18433036. DOI:10.1002/lt.21423.
			61. Mekeel KL, Moss AA, Reddy KS, **Mulligan DC**, Harold KL. Laparoscopic fenestration of giant hepatic cysts. Surg Laparosc Endosc Percutan Tech. 2008 Oct; 18(5):511-3. PMID:18936679. DOI:10.1097/SLE.0b013e31817739e7.
			62. Ko EY, Castle EP, Desai PJ, Moss AA, Reddy KS, Mekeel KL, **Mulligan DC**, Andrews PE. Utility of the endovascular stapler for right-sided laparoscopic donor nephrectomy: a 7-year experience at Mayo Clinic. J Am Coll Surg. 2008 Dec; 207(6):896-903. Epub 2008 Aug 30. PMID:19183537. DOI:10.1016/j.jamcollsurg.2008.07.013.
			63. Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, **Mulligan DC**, Moss AA, Mekeel KL, Reddy KS. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report. Clin Transpl. 2009; 407-14. PMID:20524306.
			64. Hastings D, Patel B, Torloni AS, Mookadam F, Betcher J, Moss A, Heilman R, Mazur M, Hamawi K, **Mulligan D**, Reddy K, Mekeel K, Chakkera H. Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. J Clin Apher. 2009; 24(1):28-31. PMID:19156754. DOI:10.1002/jca.20187.
			65. Heilman RL, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, **Mulligan D**, Reddy KS. Outcomes of simultaneous kidney-pancreas transplantation with positive cross-match. Transplant Proc. 2009 Jan-Feb; 41(1):303-6. PMID:19249540. DOI:10.1016/j.transproceed.2008.08.154.
			66. \*Li F, Mekeel KL, Eleid M, Harrison ME, Reddy KS, Moss AA, **Mulligan DC**. Hemobilia and pancreatitis after liver transplant biopsy. Liver Transpl. 2009 Mar; 15(3):350-1. PMID:19243004. DOI:10.1002/lt.21619.
			67. Chakkera HA, Weil EJ, Castro J, Heilman RL, Reddy KS, Mazur MJ, Hamawi K, **Mulligan DC**, Moss AA, Mekeel KL, Cosio FG, Cook CB. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol. 2009 Apr; 4(4):853-9. Epub 2009 Apr 01. PMID:19339426. PMCID:2666437. DOI:10.2215/CJN.05471008.
			68. Mekeel K, Moss A, Reddy KS, Douglas D, **Mulligan D**. Sclerosing peritonitis and mortality after liver transplantation. Liver Transpl. 2009 Apr; 15(4):435-9. PMID:19326414. DOI:10.1002/lt.21702.
			69. Mekeel KL, Moss AA, **Mulligan DC**, Chakkera HA, Hamawi K, Mazur MJ, Heilman RL, Reddy KS. Deceased donor kidney transplantation from donors with acute renal failure due to rhabdomyolysis. Am J Transplant. 2009 Jul; 9(7):1666-70. Epub 2009 May 20. PMID:19459799. DOI:10.1111/j.1600-6143.2009.02663.x.
			70. Reich DJ, **Mulligan DC**, Abt PL, Pruett TL, Abecassis MM, D'Alessandro A, Pomfret EA, Freeman RB, Markmann JF, Hanto DW, Matas AJ, Roberts JP, Merion RM, Klintmalm GB, ASTS Standards on Organ Transplantation Committee. ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation. Am J Transplant. 2009 Sep; 9(9):2004-11. Epub 2009 Jul 16. PMID:19624569. DOI:10.1111/j.1600-6143.2009.02739.x.
			71. Jaroszewski DE, Pierce CC, Staley LL, Wong R, Scott RR, Steidley EE, Gopalan RS, DeValeria P, Lanza L, **Mulligan D**, Arabia FA. Simultaneous heart and kidney transplantation after bridging with the CardioWest total artificial heart. Ann Thorac Surg. 2009 Oct; 88(4):1324-6. PMID:19766830. DOI:10.1016/j.athoracsur.2009.02.056.
			72. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, **Mulligan D**, Moss A, De Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl. 2009 Dec; 15(12):1872-81. PMID:19938138. DOI:10.1002/lt.21954.
			73. Chakkera HA, Hanson RL, Raza SM, DiStefano JK, Millis MP, Heilman RL, **Mulligan DC**, Reddy KS, Mazur MJ, Hamawi K, Moss AA, Mekeel KL, Cerhan JR. Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. Transplant Proc. 2009 Dec; 41(10):4172-7. PMID:20005362. PMCID:3478878. DOI:10.1016/j.transproceed.2009.08.063.
			74. Eleid MF, Hurst RT, Vargas HE, Rakela J, **Mulligan DC**, Appleton CP. Short-term cardiac and noncardiac mortality following liver transplantation. J Transplant. 2010; 2010. Epub 2010 Aug 12. PMID:20814597. PMCID:2931376. DOI:10.1155/2010/910165.
			75. Mekeel KL, Daley SM, Andrews PE, Moss AA, Heilman RL, Mazur MJ, Chakkera HA, Hamawi K, **Mulligan DC**, Sudhakar Reddy K. Successful transplantation of a split crossed fused ectopic kidney into a patient with end-stage renal disease. J Transplant. 2010; 2010:383972. Epub 2010 Mar 25. PMID:20368777. PMCID:2846343. DOI:10.1155/2010/383972.
			76. Heilman RL, Devarapalli Y, Chakkera HA, Mekeel KL, Moss AA, **Mulligan DC**, Mazur MJ, Hamawi K, Williams JW, Reddy KS. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant. 2010 Mar; 10(3):563-70. Epub 2010 Feb 01. PMID:20121731. DOI:10.1111/j.1600-6143.2009.02966.x.
			77. Humar A, Morris M, Blumberg E, Freeman R, Preiksaitis J, Kiberd B, Schweitzer E, Ganz S, Caliendo A, Orlowski JP, Wilson B, Kotton C, Michaels M, Kleinman S, Geier S, Murphy B, Green M, Levi M, Knoll G, Segev D, Brubaker S, Hasz R, Lebovitz DJ, **Mulligan D**, O'Connor K, Pruett T, Mozes M, Lee I, Delmonico F, Fischer S. Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report. Am J Transplant. 2010 Apr; 10(4):889-99. Epub 2010 Jan 29. PMID:20121734. DOI:10.1111/j.1600-6143.2009.02992.x.
			78. Reddy KS, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, **Mulligan D**. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin. Transplant Proc. 2010 Jul-Aug; 42(6):2006-8. PMID:20692393. DOI:10.1016/j.transproceed.2010.05.090.
			79. Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, **Mulligan DC**, Reddy KS, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Castro JC, Cook CB. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol. 2010 Sep; 5(9):1669-75. Epub 2010 Jun 17. PMID:20558559. PMCID:2974410. DOI:10.2215/CJN.09481209.
			80. Chakkera HA, Bodner JK, Heilman RL, **Mulligan DC**, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Ray RM, Beck GL, Reddy KS. Outcomes after simultaneous pancreas and kidney transplantation and the discriminative ability of the C-peptide measurement pretransplant among type 1 and type 2 diabetes mellitus. Transplant Proc. 2010 Sep; 42(7):2650-2. PMID:20832562. PMCID:3060052. DOI:10.1016/j.transproceed.2010.04.065.
			81. Grotz TE, Nagorney D, Donohue J, Que F, Kendrick M, Farnell M, Harmsen S, **Mulligan D**, Nguyen J, Rosen C, Reid-Lombardo KM. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? HPB (Oxford). 2010 Oct; 12(8):546-53. Epub 2010 Sep 02. PMID:20887322. PMCID:2997660. DOI:10.1111/j.1477-2574.2010.00213.x.
			82. Grotz TE, Nagorney D, Donohue J, Que F, Kendrick M, Farnell M, Harmsen S, Mulligan D, Nguyen J, **Rosen C**, Reid-Lombardo KM. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? HPB (Oxford). 2010 Oct; 12(8):546-53. Epub 2010 Sep 02. PMID:20887322. PMCID:2997660. DOI:10.1111/j.1477-2574.2010.00213.x.
			83. Tyson M, Castle E, Andrews P, Heilman R, Mekeel K, Moss A, **Mulligan D**, Reddy K. Early graft function after laparoscopically procured living donor kidney transplantation. J Urol. 2010 Oct; 184(4):1434-9. Epub 2010 Aug 19. PMID:20727548. DOI:10.1016/j.juro.2010.06.013.
			84. Tyson MD, Castle EP, Ko EY, Andrews PE, Heilman RL, Mekeel KL, Moss AA, **Mulligan DC**, Reddy KS. Living donor kidney transplantation with multiple renal arteries in the laparoscopic era. International Braz J Urol. 2011; 37(3):401. DOI:10.1590/S1677-55382011000300018.
			85. Heilman RL, Nijim S, Chakkera HA, Devarapalli Y, Moss AA, **Mulligan DC**, Mazur MJ, Hamawi K, Williams JW, Reddy KS. Impact of acute rejection on kidney allograft outcomes in recipients on rapid steroid withdrawal. J Transplant. 2011; 2011:583981. Epub 2011 May 15. PMID:21647349. PMCID:3103882. DOI:10.1155/2011/583981.
			86. Mekeel KL, Moss AA, **Mulligan DC**, Reddy KS. Open sphincteroplasty for benign ampullary stricture after pancreas transplantation. Am J Transplant. 2011 Feb; 11(2):399-402. Epub 2011 Jan 07. PMID:21214856. DOI:10.1111/j.1600-6143.2010.03369.x.
			87. Tyson MD, Castle EP, Ko EY, Andrews PE, Heilman RL, Mekeel KL, Moss AA, **Mulligan DC**, Reddy KS. Living donor kidney transplantation with multiple renal arteries in the laparoscopic era. Urology. 2011 May; 77(5):1116-21. Epub 2010 Dec 08. PMID:21145095. DOI:10.1016/j.urology.2010.07.503.
			88. Mekeel KL, Moss AA, **Mulligan DC**, Reddy KS. A technique for kidney retransplantation after simultaneous kidney pancreas transplantation. Transplant Proc. 2011 Jun; 43(5):1627-8. PMID:21693246. DOI:10.1016/j.transproceed.2011.03.026.
			89. Jimenez-Zepeda VH, Heilman RL, Engel RA, Carey EJ, Freeman C, Rakela J, **Mulligan DC**, Fonseca R, Stewart AK. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation. 2011 Sep 15; 92(5):570-4. PMID:21712755. DOI:10.1097/TP.0b013e318225db2c.
			90. Chakkera HA, Weil EJ, Swanson CM, Dueck AC, Heilman RL, Reddy KS, Hamawi K, Khamash H, Moss AA, **Mulligan DC**, Katariya N, Knowler WC. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care. 2011 Oct; 34(10):2141-5. PMID:21949218. PMCID:3177751. DOI:10.2337/dc11-0752.
			91. Mekeel KL, Moss AA, Reddy KS, **Mulligan DC**, Harold KL. Laparoscopic distal pancreatectomy: does splenic preservation affect outcomes? Surg Laparosc Endosc Percutan Tech. 2011 Oct; 21(5):362-5. PMID:22002275. DOI:10.1097/SLE.0b013e31822e0ea8.
			92. Mazur MJ, Lowney AC, Prigoff J, Heilman RL, Chakkera H, Moss A, **Mulligan D**, Reddy K, Hamawi K. Resolution of long-standing necrobiosis lipoidica diabeticorum (NLD) lesion after restoration of euglycemia following successful pancreas after kidney (PAK) transplantation: a case report. Transplant Proc. 2011 Nov; 43(9):3296-8. PMID:22099781. DOI:10.1016/j.transproceed.2011.10.005.
			93. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, **Mulligan DC**, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403. PMID:21850690. DOI:10.1002/lt.22417.
			94. Carey EJ, Aqel BA, Byrne TJ, Douglas DD, Rakela J, Vargas HE, Moss AA, **Mulligan DC**, Reddy KS, Chakkera HA. Pretransplant fasting glucose predicts new-onset diabetes after liver transplantation. J Transplant. 2012; 2012:614781. Epub 2012 Jan 29. PMID:22461975. PMID:3306927. DOI:10.1155/2012/614781.
			95. Rosenfeld DM, Trentman TL, Simula DV, Ivancic MG, Poterack KA, Weinmeister KP, Seamans DP, **Mulligan DC**, Noble BN. Adult live donor hepatectomy: a retrospective pilot study comparing four strategies of perioperative pain control. J Transplant Technol Res. 2012; S1-007. DOI:10.4172/2161-0991.S1-007.
			96. Tyson MD, Castle EP, Andrews PE, Heilman RL, Moss AA, **Mulligan DC**, Reddy KS. Ureteral stricture formation in laparoscopically procured living donor kidney transplantation. Can J Urol. 2012 Apr; 19(2):6188-92. PMID:22512964.
			97. Pruett TL, Blumberg EA, Cohen DJ, Crippin JS, Freeman RB, Hanto DW, **Mulligan DC**, Green MD. A consolidated biovigilance system for blood, tissue and organs: one size does not fit all. Am J Transplant. 2012 May; 12(5):1099-101. Epub 2012 Apr 09. PMID:22487495. DOI:10.1111/j.1600-6143.2011.03907.x.
			98. Kusne S, Vilchez RA, Zanwar P, Quiroz J, Mazur MJ, Heilman RL, **Mulligan D**, Butel JS. Polyomavirus JC urinary shedding in kidney and liver transplant recipients associated with reduced creatinine clearance. J Infect Dis. 2012 Sep 15; 206(6):875-80. Epub 2012 Jul 16. PMID:22802433. PMCID:3501156. DOI:10.1093/infdis/jis469.
			99. Martin AD, Mekeel KL, Castle EP, Vaish SS, Martin GL, Moss AA, **Mulligan DC**, Heilman RL, Reddy KS, Andrews PE. Laparoscopic bilateral native nephrectomies with simultaneous kidney transplantation. BJU Int. 2012 Dec; 110(11 Pt C):E1003-7. Epub 2012 Aug 09. PMID:22882539. DOI:10.1111/j.1464-410X.2012.11379.x.
			100. \*Hsieh TH, Mekeel KL, Crowell MD, Nguyen CC, Das A, Aqel BA, Carey EJ, Byrne TJ, Vargas HE, Douglas DD, **Mulligan DC**, Harrison ME. Endoscopic treatment of anastomotic biliary strictures after living donor liver transplantation: outcomes after maximal stent therapy. Gastrointest Endosc. 2013 Jan; 77(1):47-54 Epub 2012 Oct 11. PMID:23062758. DOI:10.1016/j.gie.2012.08.034.
			101. Chakkera HA, Chang YH, Bodner JK, Behmen S, Heilman RL, Reddy KS, **Mulligan DC**, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. Transplant Proc. 2013 Jan-Feb; 45(1):137-41. PMID:23375287. DOI:10.1016/j.transproceed.2012.10.023.
			102. Yadav AD, Chang YH, Aqel BA, Byrne TJ, Chakkera HA, Douglas DD, **Mulligan DC**, Rakela J, Vargas HE, Carey EJ. New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database. J Transplant 2013; 2013:269096. Doi: 10.1155/2013/269096. Epub 2013 Sep 24. PMID: 24205434.
			103. Ashman JB, Moss AA, Rule WG, Callister MG, Reddy, **Mulligan DC**, Collins JM, De Petris G, Gunderson LL, Borad M. J. Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer. Gastointest Oncol. 2013, Dec; 4 (4):352-360. PMID:24294506.
			104. Winston DJ, Vikram HR, Rabe IB, Dhillon G, **Mulligan DC**, Hong JC, Busuttil RW, Nowicki MJ, Mone, T, Civen R, Tecle S, Trivedi KK, Hocevar SN. Donor-Derived West Nile Virus Infection in Solid Organ Transplant Recipients: Report of Four Additional Cases and Review of Clinical, Diagnostic, and Therapeutic Features. Transplantation. 2014 May; 97 vol.
			105. Carpenter SG, Grimsby G, DeMasters T, Katariya N, Hewitt WR, Moss AA, Reddy KS, Castle EP, **Mulligan DC**. Robotic resection of choledochocele in an adult with intracorporeal hepaticojejunostomy and Roux-en-Y anastomosis: encouraging progress for robotic surgical treatment of biliary disease. Journal of Robotic Surgery. 2014; 8(1):77-80. DOI: 10.1007/s11701-012-0389-5.
			106. Neuberger J, Mulligan D. Liver Allocation: can we ever get it right and should we ever get it right? Hepatology. 2015 Jan;61(1):28-31. DOI: 10.1002/hep.27359. Epub 2014 Nov 20. PMID: 25130673
			107. Massie AB, Chow EK, Wickliffe CE, Luo X, Gentry SE, **Mulligan DC**, Segev DL. *“Early changes in liver distribution following implementation of Share 35*”. Am J Transplant. 2015 Mar;15(3):659-67. DOI: 10.1111/ajt.13099. PubMed PMID: 25693474

 108. Gallegos-Orozco JF, Silva AC, Batheja MJ, Chang YH, Hansen KL, Lam-Himlin D, De Petris G, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, **Mulligan DC**, Silva AM, Rakela J, Vargas HE. “*Magnetic resonance elastrography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation”*. Abdom Imaging. 2015 Apr;40(4): 795-802.DOI:10.1007/s00261-014-0310-y. PubMed PMID: 25445158.

109. **Mulligan D.** “Disparity, Liver Demand, and Access to Transplants”. Am J Transplant. 2015 Jul;15(7):1746-7. DOI: 10.1111/ajt.13302. Epub 2015 Apr 30. No abstract available. PMID: 25929170 [PubMed - in process].

110. Munoz-Abraham AS, Patron-Lozano R, Alfadda T, Judeeba S, Alkukhun A, Narayan R, Mulligan D, Morotti R, Zinter J, Geibel JP, Rodriguez-Davalos MI, *“*Extracorporeal Hypothermic Perfusion Device for Human Intestine Preservation to Decrease Ischemic Injury During Graft Transportation”. Journal of Gastrointestinal Surgery (2015) Accepted for Publication July 2015. PubMed PMID: 25929170

111. Gentry SE, Segev DL, Kaiske BL, **Mulligan DC**, Hirose R. *“Robust Models Support Redistricting Liver Allocation to Reduce Geographic Disparity”*. Transplantation. 2015 Sep;99(9):e159-60. DOI: 10.1097/TP.0000000000000834. No abstract available. PMID: 26308421 [PubMed - indexed for MEDLINE

112. Merola J, Liapakis A, **Mulligan D**, Yoo P. Non-Alcoholic Fatty Liver Disease Following Liver Transplantation: A Clinical Review. Clin Transplant. 2015 Jul 4. DOI: 10.1111/ctr.12585. [Epub ahead of print] PubMed PMID: 26147308

113. Munoz-Abraham AS, Patron-Lozano R, Narayan R, Judeeba S, Alkukhum A, Alfadda T, Belter J, **Mulligan D**, Morotti R, Zinter J, Geibel J, Rodriguez-Davalos M, “Extracorporeal Hypothermic Perfusion Device for Intestinal Graft Preservation to Decrease Ischemic Injury During Transplantation”. The Society for Surgery of Alimentary Tract (2015) Accepted Publication October 2015.[Epub ahead of print] PMID: 26487331 [PubMed - as supplied by publisher].

114. Formica RN Jr, Aeder M, Boyle G, Kucheryavaya A, Steward D, Hirose R, **Mulligan D**. *“*Simultaneous liver-kidney allocation policy: A Proposal To Optimize Appropriate Utilization Scarce Resources*”*. Am J Transplant. 2015 Nov 25. DOI: 10.1111/ajt.13631. [Epub ahead of print] PMID: 26603142 [PubMed – as supplied by publisher].

115. Munoz-Abraham AS, Patron-Lozano R, Alfadda T, Judeeba S, Alkukhun A, Narayan R, **Mulligan D**, Morotti R, Zinter J, Geibel JP, Rodriguez-Davalos MI, “Extracorporeal Hypothermic Perfusion Device for Human Intestine Preservation to Decrease Ischemic Injury During Graft Transportation”. Journal of Gastrointestinal Surgery (2015) Accepted for Publication July 2015. PubMed PMID: 25929170

116. Gentry SE, Segev DL, Kaiske BL, **Mulligan DC**, Hirose R. “Robust Models Support Redistricting Liver Allocation to Reduce Geographic Disparity”. Transplantation. 2015 Sep;99(9):e159-60. DOI: 10.1097/TP.0000000000000834. No abstract available. PMID: 26308421 [PubMed - indexed for MEDLINE].

117. Munoz-Abraham AS, Patron-Lozano R, Narayan RR, Judeeba SS, Alkukhun A, Alfadda TI, Belter JT, **Mulligan DC**, Morotti R, Zinter JP, Geibel JP, Rodriguez-Davalos MI. Extracorporeal Hypothermic Perfusion Device for Intestinal Graft Preservation to Decrease Ischemic Injury During Transportation. Gastrointest Surg. 2016 Feb;20(2):313-21.

118. Hirose R, Gentry SE, **Mulligan DC**. “Increasing the Number of Organs Available to Transplant Is Separate From Ensuring Equitable Distribution of Available Organs: Both Are Important Goals”. Am J Transplant. 2016 12. DOI: 10.1111/ajt.13577. [Epub ahead of print] No abstract available. PMID: 26757240

119. Edwards EB, Harper AM, Hirose R, **Mulligan DC.** The impact of broader regional sharing of livers: 2 year results of “Share 35”. Liver Transpl 2016 Apr; 22

 PMID: 26890858. (4):299-409. DOI: 10.1002/IT.24418

120. Nadim MK, Durand F, Kellum JA, Levitsky J, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernandez J, Francoz C, Garcia-Tsao G, Gines P, Ison MG, Kramer DJ, Mehta RL, Moreau R, **Mulligan D**, Olson, JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, Genyk YS. Corrigendum Management of the critically ill patients with cirrhosis: A multidisciplinary perspective. J Hepatol 2016 May 27. PMID: 27241199. pii: S S0168-8278(16)30185-4. DOI: 10.1016/j.jhep.2016.05.001

121. Kulkarni S, Thiessen C, Formica RN, Schilsky, **Mulligan D**, D’Aquilia R. *The Long-Term Follow-up and Support for Living Organ Donors: A Center-Based Initiative Founded on Developing a Community of Living Donors*. Am J Transplant. 2016 Aug 8. DOI: 10.1111/ajt.14005

122. Gentry SE, Hirose, **Mulligan D**. Resolving Misconceptions About Liver Allocation and Redistricting Methodology. JAMA Surg. 2016 Oct 1;151 (10):991-992. doi: 10.1001/jamasurg.2016.1315. No abstract available.

123. Hart A, Schladt DP, Zeglin J, Pyke J, Kim WR, Lake JR, Roberts JG, Hirose R, **Mulligan DC**, Kasiske BL, Snyder JJ, Israni AK. Predicating Outcomes on the Liver Transplant Waiting List in the United States: Accounting for Large Regional Variation on Organ Availability and Priority Allocation Points. Transplantation. 2016 Oct;100(10):2153-2159.

124. Tooley, JE, Bohl DD, Kulkarni S, Rodriguez-Davalos MI, Mangi A, **Mulligan DC**, Yoo. PS. Perioperative outcomes of CABG in renal transplant recipients in the United States: results from the Nationwide. Clin Transplant. 2016 Oct;30(10):1258-1263. doi: 10.1111/ctr.12816. PMID: 27440000*.*

125. Stonnington CM, Darby 2, Santucci A, Mulligan P, Pathuis P, Cuc A, Hentz JG, Zhang N, **Mulligan D**, Sood A. A Resilience Intervention Involving Mindfulness Training for Transplant Patients and their Caregivers*.* Clin Transplant 2016 Nov.30(11):1466-1472. doi: 10.111/ctr.12841

126. Merola J, Pei K, Rodriguez-Davalos M, Gan G, Deng Y, **Mulligan DC,** Davis KA. Attitudes towards organ donation among waitlisted patients: results of a cross-sectional survey. Clin Transplant. 2016 Nov.30(11):1449-1456. DOI: 10.1111/ctr.12839.

127. **Mulligan DC**. The ongoing quest to find the appropriate patients to transplant with hepatocellular carcinoma: Milan to San Francisco to Toronto and beyond. Hepatology. 2016 Dec;64(6):1853-1855. doi: 10.1002/hep.28841

128. Bhattacharya B, Maung A, Barre K, Maerz L, Rodriguez-Davalos MI, Schilsky M, **Mulligan DC**, Davis KA. Postoperative delirium is associated with increased intensive care unit and hospital length of stays after liver transplantation. Surg Res. 2017 Jan;207:223-228. doi: 10.101

129. Deshpande R, Hirose, **Mulligan D**. Liver allocation and distribution: time for a change. Curr Opin Organ Transplant. 2017 Apr;22(2):162-168. doi: 10.1097/MOT.0000000000000397.

130. Choe J, **Mulligan DC**. Liver retransplanation: Recurrent primary sclerosing cholangitis may provide better outcomes*.* [Liver Transpl.](https://www.ncbi.nlm.nih.gov/pubmed/28425147)2017 Jun;23(6):730-732. doi: 10.1002/lt.24777

131. DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, **Mulligan DC**, Dremers WK, Kawut SM, Krowka MJ, Channick RN. Predictors of Waitlist Mortality in Portopulmonary Hypertension. Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097

132. Choe J, Merola J, Kulkarni S, **Mulligan DC**. Allograft transmission of hepatitis C during the window period: Weighing the new risks and costs in era of donor shortag*e.* [See comment in PubMed Commons below](https://www.ncbi.nlm.nih.gov/pubmed/28643333#comments)[Clin Transplant.](https://www.ncbi.nlm.nih.gov/pubmed/28643333) 2017 Aug;31(8). doi: 10.1111/ctr.13022

133. Nadim MK, DiNorcia J, Ji L, Groshen S, Levitsky J, Sung RS, Kim WR, Andreoni K, **Mulligan D**, Genyk YS. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-state liver disease. [J Hepatol.](https://www.ncbi.nlm.nih.gov/pubmed/28483678) 2017 Sep;67(3):517-525. doi: 10.1016

133. Bertacco A, Dehner CA, Caturegli G, D’Amico F, Morotti R, Rodriguez MI, **Mulligan DC**, Kriegel MA, Geibel, JP. Modulation of Intestinal Microbiome Prevents

Intestinal Ischemic Injury*.* Front Physiol 2017, 8:1064

134. So HB, Khalifa AM, Yu B, Caroll C, Burger P, **Mulligan D**, MINErosion 3: Using measurements on a tilting flume-rainfall simulator facility to predict erosion rates from post-mining landscapes in Central Queensland, Australia. PLoS One.2018 Mar 28;13(3):e0194230. doi: 10.1371/journal.pone.0194230

135. Fu W, Merola J, Malinis M, Lacy J, Barbieri A, Laipakis AH, **Mulligan DC**, Yoo PS. Successful Treatment of Primary Donor-Derived Human Herpesvirus-8 Infection and Hepatic Kaposi Sarcoma in an Adult Liver Transplant Recipient*.* Transpl Infect Dis. 2018 Oct;20(5):e12966. doi: 10.1111/tid.12966. Epub 2018 Aug 23

136. Allyse M, Amer H, Coutifaris C, Falcone T, Famuyide A, Flyckt R, Gargiulo A, Heimbach J, Johannesson L, Jowsey-Gregoire S, Khan Z, Langstraat C, Levin S, McDiarmid, Mill C, **Mulligan D**, O’Neil K, Penzias A, Pfeifer S, Porrett P, Quintini C, Reindollar R, Rosen C, Silasi DA, Stewart E, Testa G, Tzakis A, Tullius SG, Penzias A, Bendikson K, Falcone T, Gitlin S, Garcia C, Hansen K, Jindal S, Kalra S, Mersereau J, Odem R, Rebar R, Reindollar R, Rosen M, Sandlow J, Schlegel P, Stoval D, American Society for Reproductive Medicine position statement on uterus transplantation:  a committee opinion. Fertil Steril. 2018; 110(4):605-610. doi: 10.1016/j.fertnstert.2018.06.017

137. Maria J Barahona, Renee M Maina, Taras Lysyy, Michele Fionotti, Giorgio Caturegli, Vanessa Baratta, Francesco D’Amico, **David Mulligan** and John P. Geibel.  Activation of the Calcium Sensing Receptor Decreases Secretagogue-Induced Fluid Secretion in the Rat Small Intestine*.* [Front Physiol.](https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F31130866&data=02%7C01%7Ccynthia.bartley%40yale.edu%7Cc2fe6d7c04c44b2d624908d745d654be%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637054659149082347&sdata=%2FjiBKrfh%2BLa8V5mieJ9v6R%2BjUOcGZaS%2Fu04YuHQ9wMk%3D&reserved=0) 2019 May 3;10:439. doi: 10.3389/fphys.2019.00439. eCollection 2019

138. Valentino PL, Emre S, Geliang G, Li l, Deng Y **Mulligan D**, Rodriguez-Davalos.  Frequency of whole-organ in lieu of split-liver transplantation over the last decade:  Children experienced increased wait time and death*.* Am J Transplant 2019 June 1 doi:  10.1111/ajt 15481

139. M Harris, j Dirito, s spindler, N Boutagy, A Feher, H Liu, S Hosgood, **D Mulligan**. Whole Organ Tomographic Imaging to Assess Viability and Response to Therapy During Ex Vivo Perfusion. Transplant International 32, 156-156, 2019

140. VM Baratta, M Barahona, **D Mulligan**, J Geibel. Glacial Acetic Acid-Induced Ulcerative Colitis Lesions Improve After Oral Calcium Carbonate Nanoparticle Therapy in a Rat Model. Diseases of the Colon & Rectum 62 (6), E46-E46, 2019

141. Maria J Barahona, Renee M Maina, Taras Lysyy, Michele Fionotti, Giorgio Caturegli, Vanessa Baratta, Francesco D’Amico, **David Mulligan** and John P. Geibel Activation of the Calcium Sensing Receptor Decreases Secretagogue-Induced Fluid Secretion in the Rat Small Intestine, Frontiers in physiology 10, 4391, 2019

142. V Baratta, MJ Barahona, **DC Mulligan**, JP Geibel. Aspirin and Ischemia in the Murine Distal Colon., Gastroenterology 156 (6), S-708, 2019

143. V Baratta, MJ Barahona, **DC Mulligan**, JP Geibel, Oral Calcium Nanoparticle Therapy Aids in the Recovery from Dss-Induced Ulcerative Colitis in the Rat Model, Gastroenterology 156 (6), S-384-S-385, 2019

144. CS Palumbo, J Batisti, R Batra, J Dopico, D Haakinson, L Hughes, **D Mulligan**. Impact of a Liver Waitlist Candidate LDLT Educational Outreach Program on Referrals and Outcomes of Donor Evaluation. American Journal of Transplantation. 19, 881-882, 2019

145. P Narayanan, C Palumbo, K Ventura, R Tomlin, L Hammers, M Joyce, **D Mulligan**. Patient Response to a Formal Living Donor Liver Transplant Educational Program. American Journal of Transplantation. 19, 875-876, 2019

146. MJ Barahona, V Baratta, J Ollodart, **D Mulligan**, JP Geibel. Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders. Future medicinal chemistry 11 (08), 847-855[3](https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1184165154172689711), 2019

147. G Tietjen, J DiRito, S Hosgood, L Bracaglia, C Albert, T Lysyy, D Deep, **D Mulligan.**  Tailoring Vascular-Targeted Nanomedicines for Delivery During Ex Vivo Organ Perfusion. American Journal of Transplantation 19, 21-21, 2019

148. DuBrock HM, Salgia RJ, Sussman NL, Bartolome SD, Kadry Z, **Mulligan DC**, Jenkins S, Lackore K, Channick RN, Kawut SM, Krowka MJ. Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes Transplant Direct. 2019 May 22;5(6):e456. doi: 10.1097/TXD.0000000000000900. eCollection 2019

149. T Lysyy, M Finotti, RM Maina, R Morotti, AS Munoz-Abraham, A Bertacco, **D Mulligan**. Human Small Intestine Transplantation: Segmental Susceptibility to Ischemia Using Different Preservation Solutions and Conditions, Transplantation Proceedings, 2020

150. JR DiRito, SA Hosgood, M Reschke, C Albert, LG Bracaglia, **DC Mulligan**. Lysis of cold‐storage‐induced microvascular obstructions for ex vivo revitalization of marginal human kidneys. American Journal of Transplantation, 2020

151. J Tefera, M Revzin, J Chapiro, L Savic, **D Mulligan**, R Batra, T Taddei. Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation. Journal of Clinical Pathology, 2020

152. OK Fix, B Hameed, RJ Fontana, RM Kwok, BM McGuire, **DC Mulligan**, ...Clinical best practice advice for hepatology and liver transplant providers during the COVID‐19 pandemic: AASLD expert panel consensus statement. Hepatology [63](https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12297533782074727616), 2020

153. K Cmunt, G Danovitch, F Delmonico, F Fynn-Thompson, A Glazier, **D Mulligan,** ...Deceased donors: Defining drug-related deaths. Clinical transplantation 34 (3), e13800, 2020.

154. JM Greco, **DC Mulligan**, PS Yoo. Salvage after Retroperitoneal Kidney Allograft Torsion, Case Reports in Transplantation, 2020

155. G Tietjen, J DiRito, S Hosgood, M Reschke, C Albert, L Bracaglia, A Vaish, **DC Mulligan**, ...Kidney cold-storage induces synthesis of fibrinogen leading to microvascular plugging following reperfusion. American Journal of Transplantation. 20, 90-90, 2020

156. D Haakinson, J DiRito, M Harris, C Albert, J Langford, C Edwards, T Lysyy, **D Mulligan**. Developing Infrastructure for High Impact Transplant Declined Human Organ Research in the US. American Journal of Transplantation. 20, 47-47, 2020

157. M Harris, J Langford, C Edwards, C Albert, T Lysyy, **D Mulligan**, P Yoo. Transplant-declined human organ research as a platform for surgical education

American Journal of Transplantation. 20, 48-48, 2020

158. Fix OK, Hamreed B, Fontana JJ, Kwok RM, McGuire BM, **Mulligan DC,** Pratt, DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. HEPATOLOGY. 2020 Jul; 72(1)287-304. doi: 10.1002/hep.31281 PMID: 32298473

159. J Merola, M Schilsky, **D Mulligan.** The Impact of COVID-19 on Organ Donation, Procurement and Liver Transplantation in the United States. Hep Communications. August 2020

160. Piotr Witkowski, Louis H. Philipson, Dixon B. Kaufman, Lloyd E. Ratner, Marwan S. Abouljoud, Melena d. Bellin, John Buse, Fouad Kandeel, Peter G. Stock, **David C. Mulligan**, James F. Markmann, Tomasz Kozlowski, Kenneth A. Andreoni, Rodolfo Alejandro, David A. Baidal, Mark A. Hardy, Amittha Wickrema, Raghavendra G. Mirmira, John Fung, Yolanda T. Becker, Michelle A. Josephson, Riotr J. Bachul, Jordan S. Pyda, Michael Charlton, J. Michael Milliis, Jason L. Gaglia, Robert J. Stratta, Jonathan A. Fridell, Silke V. Niderhaus, Rachael C. Forbes, Kumar Jayant, R. Paul Robertson, Jon S. Odorico, Marlon F. Levy, Robert C. Harland, Peter L. Abrams. Oyedolamu K. Olaitan, Raja Kandaswamy, Jason R. Wellen, Anthony J. Japour, Chirag Desai Bashoo Naziruddin, Appakalai N. Balamurugan, Rolf Barth, Camillo Ricordi. The Demise of Islet Allotransplantation in the United States: A Call for an Urgent Regulatory Update. AMERICAN JOURNAL OF TRANSPLANTATION. 29 November 2020.

161. Paula M. Oestmann, Clinton . Wang, Lynn J. Savic, Charlie A. Hamm, Sophie Startk, Isabel Schobert, Bernhard Gebauer, Todd Schlachter, MingDe Lin, Jeffrey C. Weinreb, Ramesh Batra, **David Mulligan**, Xuchen Zhang, James S. Duncan and Julius Chapiro. Deep learning-assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) on contrats-enhanced MRI of the liver. European Radiology (2021)31:4981-4990. https://doi.org/10.1007/s00330-020-07559-1

162. Chouairi F, Mullan CW, Sen S, Mori M, Fuery M, Elder RW, Lesse J, Norton K, Clark KA, Miller PE, **Mulligan D,** Formica R, Rogers JG, Jacoby D, Maulion C, Anwer M Geirrson A, Desai NR, Ahmad T. Impact of the New Heart Allocation Policy on Patients with Restrictive, Hypertrophic, or Congenital Cardiomyopathies. PLoS One. 2021 Mar 2;16(3):e0247789. Doi: 10.1371/journal.pon.0247789. eCollection 2021. PMID 33651802

163. Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, **Mulligan DC**, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ. AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease. Hepatology.2021 Feb 12:10.1002/hep.31751. doi: 10.1002/hep.31751. PMID: 3577086

164. RK Batra, **DC Mulligan**. Current Status: Meeting the Regulatory Goals of your Liver Transplant Program. Current Opinion in Organ Transplantation, 2021. Journals.lww.com

165. Justin R Boike, Bartley G Thornburg, Sumeet K. Asrani, Michael B. Fallon, Brett E. Fortune, Manhal J Izzy, Elizabeth C. Verna, Juan G Abraldes, Andrew S. Allegretti, Jasmohan S Bajaj, Scott W Biggins, Michael D Darcy, Maryjane A Faarr, Khashayar Farsad, Guadalupe Garcia-Tsao, Shelley A. Hall, Caroline C Jadlowiec, Michael J Krowka, Jeanne Laberge Edward W. Lee, **David C. Mulligan,** Mitra K Nadim, Patrick G. Northup, Riad Salem, Joseph J Shatzel, Cathryn J Shaw, Douglas A Simonetto, Jonathan Susman, K Pallav Kolli, Lisa B VanWagner, MD, ScM. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clinical Gastroenterology and Hepatology. Published July 14, 2021. DOI: <https://doi.org/10.1016/j.cgh.2021.07.018>

166. Amber R. Wilk, Sarah E. Booker, Darren E. Stewart, Alexander Wiseman, Katrina Gauntt, **David Mulligan**, Richard N. Formica. Developing simultaneous liver-kidney transplant medical eligibility criteria while providing a safety net: A 2-year review of the OPTN’s allocation policy. American Journal of Transplantation. Volume 21, Issue 11, November 2021, Pages 3593-3607. [**https://doi.org/10.1111/ajt.16761**](https://doi.org/10.1111/ajt.16761)

|  |  |
| --- | --- |
| 167. | Mullan CW, Chouairi F, Sen S, Mori M, Clark KAA, Reinhardt SW, Miller PE, Fuery MA, Jacoby D, Maulion C, Anwer M, Geirsson A, **Mulligan D**, Formica R, Rogers JG, Desai NR, Ahmad T. [Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy.](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F33714748%2F&data=05%7C01%7Cdavid.mulligan%40yale.edu%7C13d41fc3f49149a9abed08daacbcfc11%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C638012224944192750%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=J9HPnerDkhYgiLpQqzSSwc%2FwgXNNBNPj%2FkJFdT2l%2BDo%3D&reserved=0)JACC Heart Fail. 2021 Jun;9(6):420-429. doi: 10.1016/j.jchf.2021.01.010. Epub 2021 Mar 10. PMID: 33714748 |
| 168.  | Banach DB, Lopez-Verdugo F, Sanchez-Garcia J, Tran A, Gomez-Llerena A, Munoz-Abraham AS, Bertacco A, Valentino PL, Yoo P, Dembry LM, **Mulligan DC**, Ekong UD, Emre SH, Rodriguez-Davalos MI. [Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients.](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35989545%2F&data=05%7C01%7Cdavid.mulligan%40yale.edu%7C13d41fc3f49149a9abed08daacbcfc11%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C638012224944036533%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=hoXQ5U3zirI%2BNuIvGktW%2Ba8HLpJaiXzn%2FzeA0S%2Bdbxg%3D&reserved=0)Transpl Infect Dis. 2022 Aug 21:e13941. doi: 10.1111/tid.13941. Online ahead of print. PMID: 35989545 |
| 169.  | Pashankar DS, Brown T, Votto P, Follo M, Formica RN, Schilsky ML, **Mulligan DC**, Khokhar B.J [Sustained Improvement in Patient Experience by Optimizing Patient Flow in Ambulatory Settings.](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35402702%2F&data=05%7C01%7Cdavid.mulligan%40yale.edu%7C13d41fc3f49149a9abed08daacbcfc11%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C638012224944192750%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=0Mvt1KSGHbv3ex9Pr3MRMraKQRlmbCw927VM1xFxCQg%3D&reserved=0) Patient Exp. 2022 Apr 6;9:23743735221092610. doi: 10.1177/23743735221092610. eCollection 2022.PMID: 35402702 **Free PMC article.** |
| 170.  | Emamaullee J, Heimbach JK, Olthoff KM, Pomfret EA, Roberts JP, Selzner N; NALLDIG Consortium\*.[Assessment of long-term outcomes post living liver donation highlights the importance of scientific integrity when presenting transplant registry data.](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35352461%2F&data=05%7C01%7Cdavid.mulligan%40yale.edu%7C13d41fc3f49149a9abed08daacbcfc11%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C638012224944192750%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=BQknl3EjhSAdP5TqHoqObC%2FaJ2QExkoeaJKDADKTREM%3D&reserved=0)Am J Transplant. 2022 Jun;22(6):1519-1522. doi: 10.1111/ajt.17045. Epub 2022 Apr 6. PMID: 35352461 |
| 171.  | Batra RK, **Mulligan DC**. [Clinical and Ethical Framework for Liver Retransplantation Using Living Donor Grafts: A Western Perspective.](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34931433%2F&data=05%7C01%7Cdavid.mulligan%40yale.edu%7C13d41fc3f49149a9abed08daacbcfc11%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C638012224944192750%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=4oesx%2FYDU8qqhdrvJ%2B%2FYRQKomlGfyhD3H5FLgDWcddg%3D&reserved=0) [Clinical and Ethical Framework for Liver Retransplantation Using Living Donor Grafts: A Western Perspective.](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34931433%2F&data=05%7C01%7Cdavid.mulligan%40yale.edu%7C13d41fc3f49149a9abed08daacbcfc11%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C638012224944192750%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=4oesx%2FYDU8qqhdrvJ%2B%2FYRQKomlGfyhD3H5FLgDWcddg%3D&reserved=0)Liver Transpl. 2022 May;28(5):760-762. doi: 10.1002/lt.26395. Epub 2022 Jan 11. PMID: 34931433  |
| 172.  | Merola J, Gan G, Stewart D, Noreen S, **Mulligan D**, Batra R, Haakinson D, Deng Y, Kulkarni S. [Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplant.](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34793524%2F&data=05%7C01%7Cdavid.mulligan%40yale.edu%7C13d41fc3f49149a9abed08daacbcfc11%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C638012224944192750%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=lkhgVX6yK86AmSmaO8oBr0eZ%2FHEY3GPyqjxtemk1os8%3D&reserved=0)PLoS One. 2021 Nov 18;16(11):e0260000. doi: 10.1371/journal.pone.0260000. eCollection 2021. PMID: 34793524 **Free PMC article.** |
| 173.  | Boike JR, Thornburg BG, Asrani SK, Fallon MB, Fortune BE, Izzy MJ, Verna EC, Abraldes JG, Allegretti AS, Bajaj JS, Biggins SW, Darcy MD, Farr MA, Farsad K, Garcia-Tsao G, Hall SA, Jadlowiec CC, Krowka MJ, Laberge J, Lee EW, **Mulligan DC**, Nadim MK, Northup PG, Salem R, Shatzel JJ, Shaw CJ, Simonetto DA, Susman J, Kolli KP, VanWagner LB; Advancing Liver Therapeutic Approaches (ALTA) Consortium. [North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F34274511%2F&data=05%7C01%7Cdavid.mulligan%40yale.edu%7C13d41fc3f49149a9abed08daacbcfc11%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C638012224944192750%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=k8nsoVqxeFEYGdX4vIEcT9Xl3xJ1c0HYa0SoeiRJkeQ%3D&reserved=0)Clin Gastroenterol Hepatol. 2022 Aug;20(8):1636-1662.e36. doi: 10.1016/j.cgh.2021.07.018. Epub 2021 Jul 15. PMID: 34274511 **Free PMC article.**  |
| 174 | D'Amico F, Bertacco A, Finotti M, Di Renzo C, Rodriguez-Davalos MI, Gondolesi GE, Cillo U, Mulligan D, Geibel J. [Bile Microbiota in Liver Transplantation: Proof of Concept Using Gene Amplification in a Heterogeneous Clinical Scenario.](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F33796547%2F&data=05%7C01%7Cdavid.mulligan%40yale.edu%7C13d41fc3f49149a9abed08daacbcfc11%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C638012224944192750%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=phErIWIVxvgSpl2nR43il96MN1yJXkFbFhd%2BqubwjK8%3D&reserved=0)Front Surg. 2021 Mar 16;8:621525. doi: 10.3389/fsurg.2021.621525. eCollection 2021.PMID: 33796547 Free PMC article. |
| 175.  | Pawlak N, Song C, Alvi S, Schuster K, Segalini N, Kwon YK, Akoad ME, Rauf MA, Mulligan D, Aziz H. Perceptions and Early Outcomes of the Acuity Circles Allocation Policy Among Liver Transplant Centers in the United States. Transplant Direct. 2022 Dec 12;9(1):e1427. doi: 10.1097/TXD.0000000000001427. PMID: 36582673; PMCID: PMC975063 |
| 176. | Albert C, Harris M, DiRito J, Shi A, Edwards C, Harkins L, Lysyy T, Kulkarni S, Mulligan DC, Hosgood SA, Watson CJE, Friend PJ, Nicholson ML, Haakinson D, Saeb-Parsy K, Tietjen GT. Honoring the gift: The transformative potential of transplant-declined human organs. Am J Transplant. 2023 Feb;23(2):165-170. doi: 10.1016/j.ajt.2022.11.015. Epub 2023 Jan 7. PMID: 36695696. |
| 177. | Finotti M, D'Amico F, Mulligan D, Testa G. A narrative review of the current and future role of robotic surgery in liver surgery and transplantation. Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):56-68. doi: 10.21037/hbsn-21-115. Epub 2021 Aug 20. PMID: 36860258; PMCID: PMC9944521. |
| 178. | Jesse MT, Jackson WE, Liapakis A, Ganesh S, Humar A, Goldaracena N, Levitsky J, Mulligan D, Pomfret EA, Ladner DP, Roberts JP, Mavis A, Thiessen C, Trotter J, Winder GS, Griesemer AD, Pillai A, Kumar V, Verna EC, LaPointe Rudow D, Han HH; AST LDLT Consensus Conference Working Group. Living donor liver transplant candidate and donor selection and engagement: Meeting report from the living donor liver transplant consensus conference. Clin Transplant. 2023 Mar 9:e14954. doi: 10.1111/ctr.14954. Epub ahead of print. PMID: 36892182. |
| 179. | Kucukkaya AS, Zeevi T, Chai NX, Raju R, Haider SP, Elbanan M, Petukhova-Greenstein A, Lin M, Onofrey J, Nowak M, Cooper K, Thomas E, Santana J, Gebauer B, Mulligan D, Staib L, Batra R, Chapiro J. Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning. Sci Rep. 2023 May 10;13(1):7579. doi: 10.1038/s41598-023-34439-7. PMID: 37165035; PMCID: PMC10172370. |
| 180. | Ivanics T, Claasen MP, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Quintini C, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ. Living Donor Liver Transplantation (LDLT) for Hepatocellular Carcinoma (HCC) within and Outside Traditional Selection Criteria: A Multicentric North American Experience. Ann Surg. 2023 Jul 31. doi: 10.1097/SLA.0000000000006049. Epub ahead of print. PMID: 37522174. |
| 181. | Deshpande R, Shah R, Mulligan DC. New Allocation Systems: Principles and Processes (Pro). Transplantation. 2023 Aug 30. doi: 10.1097/TP.0000000000004786. Epub ahead of print. PMID: 37644663. |
| 182. |  |

***Book Chapters***

* + - 1. Rakela J, Douglas DD, Kalathil S, **Mulligan DC**. Survival following liver transplantation. In: Maddrey WC, Schiff ER, Sorrell MF, editors. Transplantation of the Liver. 3rd Edition. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 469-77. (Book chapter)
			2. Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, **Mulligan DC**, Moss AA, Mekeel KL, Reddy KS. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients – case report. In: Clinical Transplants 2009. Los Angeles: Terasaki Foundation Laboratory; 2010. p. 13-20. (Book chapter)
			3. Kusne S, **Mulligan DC**. Risks and epidemiology of infections after liver transplantation. In: Bowden RA; Ljungman P; Snydman DR editor. Transplant infections. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2010. p. 162-78. (Book chapter)
			4. Mekeel KL, **Mulligan DC**. What hepatologists should know about liver transplant surgery. In: Talley NJ; Lindor KD; Vargas HE. Practical gastroenterology and hepatology. Liver and biliary disease. Chichester; Hoboken: Wiley-Blackwell; 2010. p. 305-16. (Practical Gastroenterology and Hepatology.) (Book chapter)
			5. Patron R, Kusne S, **Mulligan DC**, Risks and epidemiology of infections after liver transplantation. In. Bowden RA; Ljungman P; Snydman DR editor. Transplant

Infections. 4th ed. Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins; 2015 (Book Chapter)

1. Yoo, P, **Mulligan DC.** What hepatologists should know about liver transplant surgery. In: Practical Gastroenterology and Hepatology Board Review Toolkit, 2nd edition, edited by Nicholas Talley, Kenneth DeVault, Michael Wallace, Bashar Aqel, and Keith Lindor. Wiley-Blackwell; 2016. (Book chapter)
2. Invited manuscript for Clinical Liver Disease, "Changes in UNOS Policy for Simultaneous Liver Kidney Allocation" by Merola, Jonathan; Formica, Richard; **Mulligan, David**
3. Invited review for Controversies in Transplantation, “Outcomes and disparities in liver transplantation will be improved by redistricting” by **David Mulligan** and Rytaro Hirose
4. Ramesh K. Batra and **David C. Mulligan**, Trends and the Current Status of Living Donor Liver Transplants. Liver Research and Clinical Management

***Textbooks***

1. Liver Transplantation: State of the Art

***Editorials***

1. Post DJ, Douglas DD, **Mulligan DC**. Immunosuppression in liver transplantation. Liver Transpl. 2005 Nov; 11(11):1307-14. PMID:16237688.
2. **Mulligan DC**. A worldwide database for living donor liver transplantation is long overdue. Liver Transpl. 2006 Oct; 12(10):1443-4. PMID:17004258. DOI:10.1002/lt.20925.
3. **Mulligan D**. Living donor liver transplantation and donor graft size: how small can we go to reduce risk to the donor and what is the cost to the recipient? Liver Transpl. 2009 Nov; 15(11):1392-4. PMID:19877257. DOI:10.1002/lt.21922.
4. **Mulligan DC**. Living donor safety during the performance of hepatectomy. Liver Transpl. 2012 Oct; 18(10):1134-5. PMID:22821707. DOI:10.1002/lt.23514.

***Letters***

1. **Mulligan D**, Abecassis M, Johnson M. When disaster strikes: donor deaths are treated with intense scrutiny, but broader sharing of information to benefit all living donors should be implemented. Am J Transplant. 2011 Jul; 11(7):1540-1; author reply 1542. Epub 2011 Jun 14. PMID:21672145. DOI:10.1111/j.1600-6143.2011.03586.x.

***Case Reports, Technical Notes, Letters***

1. Fu W, Merola J, Malinis M, Lacy J, Barbieri A, Liapakis AH, **Mulligan DC**, Yoo PS. Successful treatment of primary donor-derived human herpes virus-8 infection and hepatic and hepatic Kaposi Sarcoma in adult liver transplant recipient. Transplant Infectious Disease: An Official Journal of the Transplantation Society 2018, 20:e12966.